Clinical Trials on Alzheimer’s Disease

Preliminary Program

PALAU DE CONGRESSOS DE CATALUNYA
Barcelona, October 24-27, 2018

www.ctad-alzheimer.com
Organizing and Scientific Committees ................................................ p. 3
Keynote Speakers ...................................................................................... p. 4
Lifetime Achievement Award ................................................................... p. 6
Program at a glance .................................................................................. p. 7
- Wednesday, October 24 ................................................................. p. 9
- Thursday, October 25 ...................................................................... p. 10
- Friday, October 26 ........................................................................... p. 14
- Saturday, October 27 ...................................................................... p. 18
Theme 1. Clinical trials: Methodology .................................................. p. 22-24
Theme 2. Clinical trials: Results ............................................................. p. 25-27
Theme 3. Clinical trials: Imaging ............................................................. p. 28-29
Theme 4. Clinical trials: Biomarkers including plasma ....................... p. 30-34
Theme 7. Behavioral disorders and clinical trials ............................... p. 43
Theme 8. Health economics and clinical trials ..................................... p. 44
Theme 9. Epidemiology and clinical trials ............................................. p. 45-46
Theme 11. New therapies and clinical trials ......................................... p. 48-49
Our sponsors .......................................................................................... p. 50
Registration / Accommodations ......................................................... p. 51

Our sponsors................................................................................................ p. 50
Registration / Accommodations ......................................................... p. 51
CTAD Organizing Committee

Jacques Touchon MD, PhD
University
Hospital of Montpellier
France

Paul Aisen MD
Alzheimer’s
Therapeutic Research Institute (ATRI)
University of Southern California (USC),
San Diego, USA

Bruno Vellas MD, PhD
University
Hospital of Toulouse
France

Mike Weiner MD
University of California
San Francisco (UCSF)
USA

CTAD Scientific Committee

Susan ABUSHAKRA (San Francisco)
Paul AISEN (San Diego)
Kaj BLENNOW (Molndal)
Merce BOADA (Barcelona)
Maria CARRILLO (Chicago)
Mony John DE LEON (New York)
Steven DEKOSKY (Miami)
Rachelle DOODY (Basel)
Bruno DUBOIS (Paris)
Howard FELDMAN (Vancouver)
Nick FOX (London)
Giovanni B. FRISONI (Brescia, Geneva)
Lutz FROELICH (Mannheim)
Serge GAUTHIER (Montreal)
Ezio GIACOBINI (Geneva)
Michael GRUNDMANN (San Diego)
Harald HAMPEL (Paris)
Takeshi IWATSUBO (Tokyo)
Ara KHACHATURIAN (Washington DC)
Zaven KHACHATURIAN (Washington DC)
Virginia LEE (Philadelphia)

Constantine G. LYKETSOS (Baltimore)
José Luis MOLINUEVO (Barcelona)
Jean-Marc ORGOGOZO (Bordeaux)
Ronald PETERSEN (Minnesota)
Craig W. RITCHIE (Edinburgh)
Augustin RUIZ (Barcelona)
Robert RISSMAN (San Diego)
Stephen SALLOWAY (Providence)
Rachel SCHINDLER (New York)
Philip SCHELTENS (Amsterdam)
Lon SCHNEIDER (Los Angeles)
Eric SIEMERS (Philadelphia)
Peter SNYDER (Rhode Island)
Reisa SPERLING (Boston)
Yaakov STERN (New York)
Jacques TOUCHON (Montpellier)
John TROJANOWSKI (Philadelphia)
Bruno VELLAS (Toulouse)
Michael W. WEINER (San Francisco)
Bengt WINBLAD (Stockholm)
«Blood biomarkers for AD clinical trials»
Randall Bateman, MD, PhD
Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, St. Louis, USA
Dr. Randall Bateman, the Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, is the PI of the Dominantly Inherited Alzheimer Network (DIAN) and DIAN Trials Unit which coordinates with pharmaceutical, regulatory, and patient advocacy groups for clinical trials in dominantly inherited Alzheimer’s disease. Dr. Bateman’s laboratory investigates the causes and future diagnosis and treatments of Alzheimer’s disease utilizing a wide variety of assays and techniques. His lab measures the pathophysiology of Alzheimer’s disease in humans utilizing amyloid-beta, apolipoprotein E, APP, and tau protein kinetics. His work has been supported by the NIH, foundations, and Pharma, and he has consulted for the FDA, NIH and Pharma. He has served as a co-investigator on multiple multi-site trials including ADNI and AD clinical trials. Dr. Bateman mentors junior faculty members, fellows, and students, all successful in their desired career trajectory. His contributions have been recognized with awards from the AlzForum Community, Alzheimer’s Association (Zenith Award), Scientific American, the Glenn Award for Aging Research, and the MetLife Foundation.

«What have we learned from Aducanumab?»
Samantha Budd Haeberlein, PhD
Vice President of Alzheimer’s Disease Discovery & Development, Biogen, Boston, USA
Samantha Budd Haeberlein, Ph.D., joined Biogen in February 2015 as Vice President of Alzheimer’s Disease Discovery & Development. Dr. Budd Haeberlein was previously Vice President of Translational Science at AstraZeneca where for fifteen years she led multi-disciplinary teams and functions across Research, Strategy, Translational Medicine and Clinical Development in the US, Canada and Sweden. Dr. Budd Haeberlein has a BSc (Hons.) and PhD in Biochemistry from the University of Dundee in Scotland, and conducted research at Brigham & Women’s Hospital Harvard Medical School in Boston, and at The Burnham Institute in San Diego.

«Anti-Tau Treatments: Potential, Challenges, and Progress»
Lennart Mucke, MD
Director of the Gladstone Institute of Neurological Disease and Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco (UCSF), USA
Dr. Mucke is the founding director of the Gladstone Institute of Neurological Disease and holds joint appointments as the Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco. He trained at the Free University Berlin, the Georg-August University and the Max Planck Institute for Biophysical Chemistry in Göttingen, the Cleveland Clinic, the Massachusetts General Hospital and Harvard Medical School, and The Scripps Research Institute. Dr. Mucke’s research focuses on mechanisms that result in functional deficits in Alzheimer’s disease and other cognitive disorders. He has generated informative experimental models of these conditions and used them to identify novel strategies to prevent neurological decline. For his contributions, Dr. Mucke has received the Potamkin Prize, MetLife Foundation Award for Medical Research, Kalid Iqbal Lifetime Achievement Award, Zenith Award, American Pacesetter Award, MERIT Award, and an Award for Excellence in Direct Teaching and Mentoring. He is a member of the American Neurological Association and the Association of American Physicians, chairs the Senate of the German Center for Neurodegenerative Diseases, and has served on the Medical and Scientific Advisory Council of the Alzheimer’s Association and on the National Advisory Council on Aging for the NIH.
«How BIG and GOOD Data are revolutionizing Neurodegenerative Disease Research»

Cristina Sampaio, MD, PhD
Chief Medical Officer, CHDI Foundation, Princeton, USA

Professor Cristina Sampaio joined CHDI Foundation as Chief Clinical Officer 6 years ago. She also holds the position of Professor of Clinical Pharmacology and Therapeutics at Faculdade de Medicina de Lisboa (currently on unpaid leave). At CHDI Professor Sampaio oversees an extensive portfolio of clinical projects ranging from experimental medicine, through biomarker and rating scale development to support drug development activities, to the development and maintenance of a global clinical research platform, Enroll-HD. Professor Sampaio spent 25 years of her career in academia where her primary research interests centered on clinical research methodology, clinical trial design, and related aspects of meta-research applied to movement disorders. Together with several colleagues she founded the Cochrane Movement Disorders Group (MovDisCRG) and became its coordinating editor in 1996, a position that she has shared with Professor João Costa from 2013 to 2018. She is now an Editor of The MovDisCRG. Professor Sampaio published 170 peer review papers and book chapters. From 1998 to 2011, Professor Sampaio was a member of the Committee on Human Medicinal Products and the Scientific Advice Working Party at the European Medicines Agency. During this period, she had a very active role in the development of the standards of regulatory science for CNS medicinal products in the European Union. She was rapporteur, coordinator, or assessor of over 400 medicinal products files submitted to EMA for licensing or scientific advice and she coordinated the first clinical biomarker qualification in the EU. Professor Sampaio obtained her MD in 1986 and her PhD in clinical pharmacology in 1997 from the University of Lisbon. She is a board-certified clinical pharmacologist, receiving neurological training in the Neurology department of Hospital St Maria in Lisbon. She was a staff member of the Movement Disorders Clinic from 1988 to 2011, President of the Portuguese Movement Disorders Society 2008−2012, and Chair of the Evidence-based Medicine Committee of the International Parkinson and Movement Disorder Society 2010−2014.

«Combination therapy in AD»

Daniel M. Skovronsky, MD, PhD
Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA

Dr. Daniel M. Skovronsky, serves as Senior Vice President of Clinical and Product Development at Eli Lilly and Company. Dr. Skovronsky is responsible for developing the Lilly pipeline of molecules. He was the Founder, Chief Executive Officer and President at Avid Radiopharmaceuticals Inc. Dr. Skovronsky founded Avid Radiopharmaceuticals in 2004. Prior to establishing the firm, he served as Scientific Director of High Throughput Screening and Drug Discovery at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. Dr. Skovronsky served as Vice President of Radiopharmaceutical Development at Theracor Pharmaceuticals. He served as a Member of Advisory Board of Safeguard Sciences, Inc., until October 21, 2015 and previously served as a Member of its Life Sciences Advisory Board. Dr. Skovronsky serves as a Director of Avid Radiopharmaceuticals, Inc. He has more than 20 peer-reviewed publications and two NIH-funded grants on Alzheimer’s disease research. He is the recipient of numerous scientific and business awards and was named by the Philadelphia Business Journal as one of their Forty under Forty business leaders in the region. Dr. Skovronsky received the Ernst & Young Entrepreneur Of The Year 2009 Award in the Emerging Company category, which recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses. He trained as a resident in Pathology and completed a Fellowship in Neuropathology at the Hospital of the University of Pennsylvania. Dr. Skovronsky received his MD and PhD from the University of Pennsylvania and did BS degree in Molecular Biochemistry at Yale University.
Rachelle Doody MD, PhD is the Global Head of Neurodegeneration in Pharma Development, Neuroscience for Roche Pharmaceutical Company and its US entity, Genentech. Prior to joining Genentech/Roche in September, 2016, Dr. Doody was the Effie Marie Cain Chair in Alzheimer’s Disease Research at Baylor College of Medicine, in Houston, Texas where she founded and directed the Alzheimer’s Disease and Memory Disorders Center over a period of 27 years.

While at Baylor, she published over 200 original research articles, served on the steering committees for the National Institutes of Health-funded Alzheimer’s Disease Cooperative Study (ADCS) and Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the executive committee for the Alzheimer’s Therapeutic Research Institute (ATRI).

In her role as a practicing Neurologist, Dr. Doody was elected to Best Doctors in America from 1996-2016. She has received many awards from professional and civic groups, including Distinguished Alumni Award from Rice University in 2009 and Distinguished Faculty Award from Baylor College of Medicine in 2011.
Wednesday, October 24

4.00 - 4.30 p.m. Opening Ceremony and CTAD Lifetime Achievement Award

4.30 - 5.00 p.m. Keynote 1 - Blood biomarkers for AD clinical trials

5.00 - 6.00 p.m. Symposium 1 - APECS trial of the BACE1 inhibitor verubecestat for prodromal Alzheimer’s disease

6.00 - 6.30 p.m. Late breaking oral communications

Thursday, October 25

8.30 - 10.00 a.m. Oral communications

10.00 - 10.30 a.m. Coffee break and poster session

10.30 - 11.30 a.m. Symposium 2 - Is BACE1 a suitable drug target for prevention and treatment of Alzheimer’s disease?

11.30 - 12.30 p.m. Oral communications

12.30 - 1.30 p.m. Lunch and poster session

1.30 - 2.00 p.m. Keynote 2 - What have we learned from Aducanumab?

2.00 - 2.30 p.m. Late breaking oral communications

2.30 - 3.30 p.m. Symposium 3 - Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD

3.30 - 4.30 p.m. Oral communications

4.30 - 5.00 p.m. Coffee break and poster session

5.00 - 6.00 p.m. Symposium 4 - Aβ blood based test as surrogate markers of cortical amyloid pathology for clinical trials on Alzheimer’s disease.
Friday, October 26

8.30 - 10.00 a.m. Oral communications
10.00 - 10.30 a.m. Coffee break and poster session
10.30 - 11.00 a.m. Keynote 3 - Anti-Tau treatments: Potential, challenges, and progress
11.00 - 11.30 a.m. Late Breaking communications
11.30 - 12.30 p.m. Symposium 5 - Towards the Development of a Complete Solution for Patients with Alzheimer’s Disease (AD)
12.30 - 1.30 p.m. Lunch and poster session
1.30 - 2.45 p.m. Oral communications
2.45 - 3.30 p.m. Late Breaking communications
2.45 - 4.00 p.m. Coffee break and poster session
4.00 - 4.30 p.m. Keynote 4 - Combination therapy in AD
4.30 - 5.00 p.m. Symposium 6 - Endpoints for early Alzheimer’s disease clinical trials: Interpretation and application of the draft FDA guidance

Saturday, October 27

8.30 - 9.15 a.m. Presentation and panel discussion: AMBAR (Alzheimer’s Management By Albumin Replacement) Phase IIb/III Results
9.15 - 9.45 a.m. Keynote 5 - How BIG and GOOD Data are revolutionizing neurodegenerative disease research
9.45 - 10.15 a.m. Coffee break and poster session
10.15 - 11.15 a.m. Oral communications
11.15 - 12.15 p.m. Symposium 7 - Disclosure of Alzheimer’s risk biomarkers to cognitively normal older adults
12.15 - 1.15 p.m. Lunch and poster session
1.15 - 3.45 p.m. Oral communications
3.45 p.m. End of conference
Opening Ceremony and CTAD Lifetime Achievement Award
Jacques Touchon, Paul Aisen, Bruno Vellas, Milke Weiner, Merce Boada, Jose Luis Molinuevo
The recipient of this year’s CTAD Lifetime Achievement Award is Rachelle S. Doody M.D., Ph.D. Global Head of Neurodegeneration, Roche, Basel - Switzerland for her work dedicated to academic and industrial research in AD clinical trials

Keynote 1
Blood biomarkers for AD clinical trials
Randall Bateman, MD, PhD - Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, St. Louis, USA

Symposium 1
APECS trial of the BACE1 inhibitor verubecestat for prodromal Alzheimer’s disease
Symposium moderator: Jeffrey L. Cummings, MD, ScD, Cleveland Clinic, Las Vegas, NV, USA
Communication 1: Results from the APECS trial
Michael F. Egan, MD, Tiffini Voss, MD, Yuki Muktai, MD, James Kost, PhD, Paul S Aisen, MD, Jeffrey L. Cummings, MD, ScD, Pierre N. Tariot, MD, Bruno Vellas, MD, PhD, Christopher H. van Dych, MD, Ying Zhang, PhD, Wen Li, PhD, Christine Furteh, BS, Erin Mahoney, BA, Lyn Harper Mozley, PhD, Yi Mo, PhD, Cyrille Sur, PhD, David Michelson, MD
Merck & Co., Inc., Kenilworth, NJ, USA *University of Southern California, San Diego, CA, USA *Cleveland Clinic, Las Vegas, NV, USA *Banner Alzheimer’s Institute, Phoenix, AZ, USA *Gerontopole, INSERM U 1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France *Yale University School of Medicine, New Haven, CT, USA

Communication 2: Panel discussion
Paul S. Aisen, MD, Maria C. Carrillo, PhD, Pierre N. Tariot, MD, Bruno Vellas, MD, PhD
*University of Southern California, San Diego, CA, USA *The Alzheimer Association, Chicago, IL, USA *Banner Alzheimer’s Institute, Phoenix, AZ, USA *Gerontopole, INSERM U 1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France

Late Breaking Oral communications

LBI - Results from the phase 2 NAVIGATE-AD clinical trial evaluating LY3202626 BACE inhibitor in patients with mild Alzheimer’s disease dementia
Albert C Lo1, Cynthia Duggan Evans1, Michele Mancini1, Qin Lin, Hong Wang1, Peng Liu, Sergey Shcherbinin1, Ming Lu1, Arnaud Charil1, Brian A Willis1; for the NAVIGATE-AD Study Investigators
1Eli Lilly and Company, Indianapolis, IN, USA, 2Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, USA, 3Eli Lilly and Company, Indianapolis IN, USA; now at Eisai Inc, Woodcliff Lake, NJ

LB2 - TOMMORROW: a trial to delay the onset of MCI due to AD and qualify a genetic biomarker algorithm: topline results
Robert Alexander, MD1, Daniel K. Burns, PhD1, Kathleen A. Welsh-Bohmer, PhD1, Carl Chiang, PhD1, Meredith Culp, BS1, Janet O’Neil, MBA1, Brenda L. Plassman, PhD1, Craig Metz, PhD1, Deborah Yarbrough, MS, MBA1, Jingtao Wu, PhD1, Rebecca Evans, MD1, Kumar Budur, MD1, Stephen K. Brannan, MD1, Ann M. Saunders, PhD2, Emiliangelo Ratti, PhD1; for the TOMMORROW Study Investigators
1Takeda Development Center Americas, Inc., Cambridge, MA, USA, 2Zinfandel Pharmaceuticals, Inc., Durham, NC, USA, 3Duhe University Bryan ADRC, Durham, NC, USA, 4Takeda Development Center Americas, Inc., Deerfield, IL, USA
Oral communications

8.30 - 10.00 a.m.

OC1 - Phase 2a trial of AZD0530 evaluating 18F-FDG PET, safety, and tolerability in mild Alzheimer’s dementia
Christopher H. van Dyck, MD,1 Haakon B. Nygaard, MD, PhD2, Kewei Chen, PhD1, Michael C. Donohue, PhD2, Rema Raman, PhD2, Robert A. Rissman, PhD2, James B. Brewer, MD, PhD1, Robert A. Koepppe, PhD3, Tiffany W. Chow, MD4, Michael S. Rafii, MD4, R. Scott Turner, MD, PhD1, Jeffrey A. Kaye, MD4, Seth A. Gale, MD3, Eric M. Reiman, MD4, Paul S. Aisen, MD5, Stephen M. Strittmatter, MD, PhD1
1Yale University School of Medicine, New Haven, USA 2The University of British Columbia, Vancouver, Canada 3Banner Alzheimer's Institute, Phoenix, USA 4Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, USA 5University of California San Diego, La Jolla, USA

8.45 - 9.00 a.m.

OC2 - Primary results from a phase II/III trial of intranasal insulin: A novel multi-target molecule and delivery mode for AD therapeutics
Suzanne Craft, PhD1, Rema Raman, PhD2, Tiffany Chow, MD2, Michael S Rafii, MD2, Robert A. Rissman, PhD1, James B. Brewer, MD1, Michael Donohue, PhD2, Chung-Kai Sun, MS1, Kelly Harless2, Devon Gessert1, Paul S. Aisen, MD2
1Wake Forest School of Medicine, Winston-Salem, USA, 2University of Southern California, Los Angeles, USA

9.00 - 9.15 a.m.

OC3 - Phase3 clinical trial for a novel and multi-targeted oligosaccharide in patients with mild-moderate AD in China
Shifu Xiao, MD1, Zhenxin Zhang, MD2, Meiyu Geng, PhD3, GV-971 Study Group
1Department of Gerontology, Shanghai Mental Health Center, Shanghai Jiao Tong University, Shanghai, China 2Peking Union Medical College Hospital, Beijing, China 3State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

9.15 - 9.30 a.m.

OC4 - Active Anti-amyloid Immunotherapy with UB-311 Vaccine: Design, baseline data and study update of a Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study
Ajay Verma, Hui Jing Yu, Hui-Chen Chen, and Chang Yi Wang on behalf of the UB-311 Phase IIa Study Team
United Neuroscience, Inc. Hauppauge, NY, USA

9.30 - 9.45 a.m.

OC5 - Elenbecestat in MCI-to-moderate Alzheimer’s disease: Safety and effectiveness as measured by amyloid PET and the ADCOMS clinical endpoints
Shau Yu Lynch, PhD1, June Kaplow, PhD1, Jim Zhao, MS, MM1, Shobha Dhadda, PhD1, Johan Luthman, PhD, DDS1, Bruce Alba, PhD1
1Eisai Inc., Woodcliff Lake, NJ, USA

9.45 - 10.00 a.m.

OC6 - ALLOPREGNANOLONE regenerative therapeutic for mild cognitive impairment and mild Alzheimer’s disease: Phase Ib/2a outcomes update
Roberta D. Brinton, PhD1, Gerson D. Hernandez, MD, MPH1, Naoko Kono, MPH2, Claudia M. Lopez, BS1, Christine Sollinstny, PhD1, Kathleen Rodgers, PhD1, Jin Gam, PhD1, Dogu Aydogan, PhD1, Yonggang Shi, PhD1, Sonia Pawluczyn, MD1, Meng Law, MD1, Wendy Mach, PhD2, Lon Schneider, MD, MS2
1Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA 2Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA 3School of Pharmacy, University of Southern California, Los Angeles, CA, USA 4USC Institute for Neuroimaging and Informatics, University of Southern California, Los Angeles, CA, USA 5Department of Psychiatry & The Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA 6Department of Radiology, University of Southern California, Los Angeles, CA, USA

10.00 - 10.30 a.m.

Coffee break and poster session
Symposium 2
Is BACE1 a suitable drug target for prevention and treatment of Alzheimer’s disease?

Symposium moderator: Randall J. Bateman, MD, Department of Neurology, St. Louis, MO, USA

Communication 1: Physiological substrates of BACE1: safety issues or biomarkers?
Stefan F. Lichtenthaler, PhD German Center for Neurodegenerative Diseases (DZNE) and Technical University of Munich (TUM), Germany

Communication 2: Secretase inhibitors in AD prevention trials: optimizing success and mitigating risk.
Eric McDade, DO, Department of Neurology, St. Louis, MO, USA

Communication 3: Considerations and lessons learned for the design and implementation of AD clinical trials evaluating BACE inhibitors.
Bruce Albala, PhD and Johan Luthman, PhD; Eisai, Inc., NJ, USA

Oral communications

11.30 - 11.45 a.m.
OC7 - Impact of Amyloid PET on the management of cognitively impaired patients: Results from the IDEAS study
Gil D. Rabinovici,1 Constantine Gatsonis,2 Charles Apgar,3 Kiran Chaudhary,1 Ilana Careen,2 Lucy Hanna,2 James Hendrix,2 Bruce E. Hillner,3 Cynthia Olson,1 Orit Lesman-Segev,1 Justin Romanoff,1 Barry A. Siegel,1 Rachel A. Whitmer,2 Maria C. Carrillo,3 on behalf of the IDEAS investigators.
1Department of Neurology, University of California San Francisco; 2Center for Statistical Sciences, Brown University; 3American College of Radiology, “Alzheimer’s Association,” 4Department of Medicine, Virginia Commonwealth University, 5Department of Radiology, Washington University, 6Division of Research, Kaiser Permanente

11.45 - 12.00 p.m.
OC8 - Safety and efficacy of estrogen receptor-β targeted PhytoSERM formulation for cognitive complaints and vasomotor symptoms: Phase Ib/2a trial outcomes
Lon S. Schneider, MD1, Gerson Hernandez MD MPH2, Liqin Zhao PhD3, Sonia Pawluczyn MD1, Wendy J. Mack, PhD4, Roberta D. Brinton PhD2
1Keck School of Medicine of the University of Southern California, Los Angeles, USA, 2University of Arizona, Center for Innovation in Brain Science, Tucson, USA, 3University of Kansas, USA

12.00 - 12.15 p.m.
OC9 - Interim safety and efficacy results of pilot trial of GM-CSF/sargramostim in mild to moderate AD
Huntington Potter, PhD Jonathan H. Woodcock, Timothy Boyd, Stefan H. Sillau, Thomas Borges, Brianne M. Bettcher, Joseph Daniels
Rocky Mountain Alzheimer’s Disease Center, Department of Neurology, University of Colorado School of Medicine

12.15 - 12.30 p.m.
OC10 - Untangled – peptide-based inhibitors of tau aggregation as a potential treatment for Alzheimer’s disease
David Allsop PhD1,2, Anthony Aggidis MSC1, Nigel Fullwood PhD1, Mark Taylor PhD1,2, Penny Foulds PhD1,2, Shoon Vincent PhD2, Mark Dale MD2
1Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK, 2Peptide Innovations Limited, Affiliated Company of MAC Research, Blackpool, UK

Lunch and poster session

1.30 - 2.00 p.m.
Keynote 2
What have we learned from Aducanumab?
Samantha Budd Haeberlein, PhD - Vice President of Alzheimer’s Disease Discovery & Development, Biogen, Boston, USA
Late Breaking Oral communications

2.00 - 2.30 p.m.

**LB3 - Lu AF205I3, an active immunotherapy against amyloid beta, in development for patients in early stages of Alzheimer’s disease**

Bjørn Sperling, MD1, Lars Østergaard Pedersen, PhD1, Neli Boneva, MD1, Dorthe Daugaard, MD1, Yudong Zhao, PhD1

1H. Lundbeck A/S, Valby, Denmark

2.15 - 2.30 p.m.

**LB4 - Predictors of [18F]flortaucipir (tau) load in Alzheimer’s disease and other neurodegenerative disorders**

Oskar Hansson, MD, PhD2,3, Gil D. Rabinovici MD, PhD3, Chul H. Lyoo, MD, PhD4 & Rik Ossenkoppele, PhD1,5

1Lund University, Clinical Memory Research Unit, Lund, Sweden; 2Memory Clinic, Skåne University Hospital, Malmö, Sweden; 3Department of Neurology, University of California San Francisco, San Francisco, USA; 4Memory and Aging Center; 5Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea; 6VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands

Symposium 3

Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD

Eisai Inc, Woodcliff Lake, NJ, USA

Oral communications

3.30 - 4.30 p.m.

**OC11 - Safety and efficacy of lemborexant for sleep-wake regulation in patients with irregular sleep wake rhythm disorder and Alzheimer’s disease dementia**

Margaret Moline, PhD1, Mohammad Bsharat, PhD1, Manuel Kemethofer, MSc2, Gleb Filippov, MD, PhD1, Naoki Kubota, MPharm3, Patricia Murphy, PhD1

1Eisai, Inc., Woodcliff Lake, USA; 2The Siesta Group, Vienna, Austria; 3Eisai Co. Ltd., Tokyo, Japan

3.45 - 4.00 p.m.

**OC12 - Tau PET imaging as a screening tool for clinical trials of disease modifying therapies**

Adam S Finsher1, Michael J Pontecorvo1, Michael D Devous3, Ming Lu1, Sergey Scherbinin1, Anupa K Arora1, Mark A Minum2

1Eli Lilly & Co, Indianapolis, IN, USA; 2Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA

4.00 - 4.15 p.m.

**OC13 - BACE inhibition by verubecestat produces a rapid, non-progressive reduction in brain and hippocampal volume in Alzheimer’s disease**

Cyrille Sur, PhD1, James Kost, PhD1, David Scott, PhD2, Katarzyna Adamczuk, PhD2, Nick C Fox, PhD1, Jeffrey Cummings, MD, ScD2, Pierre Tariot, MD1, Paul Aisen, MD1, Bruno Vellas, MD, PhD2, Tiffini Voss, MD1, Yukie Mulkai, MD1, David Michelson, MD, Michael Egan, MD1

1Merck & Co., Inc, Kenilworth, NJ, USA; 2Bioclinica, Newark, CA, USA; 3Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, MO, USA; 4Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, MO, USA; 5University of California San Diego, San Diego, CA, USA; 6Toulouse University Hospital, Toulouse, France

4.15 - 4.30 p.m.

**OC14 - Distinct Tau PET Patterns in Atrophy-Defined Subtypes of Alzheimer’s disease**

Rik Ossenkoppele, Ph.D.1,2, Gil D. Rabinovici, M.D.1, Chul H. Lyoo, M.D., Ph.D.1 & Oskar Hansson, M.D., Ph.D.1,5

1Lund University, Clinical Memory Research Unit, Lund, Sweden; 2VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands; 3Department of Neurology, University of California San Francisco, San Francisco, USA; 4Memory and Aging Center; 5Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea; 6Memory Clinic, Skåne University Hospital, Malmö, Sweden

Coffee break and poster session
Symposium 4
Aβ blood based test as surrogate markers of cortical amyloid pathology for clinical trials on Alzheimer’s disease.

Moderator: Pedro Pesini PhD. Araclon Biotech-Grifols, Spain.

Communication 1: Developing Aβ blood based test into pre-screening tools for clinical trials in early stages of AD
Victor L. Villemagne, M.D. Dept of Molecular Imaging & Therapy, Austin Health, Dept of Medicine, The University of Melbourne.

Communication 2: Plasma ratio of total Aβ42 to total Aβ40 in amnestic MCI patients is associated with FDG-PET, amyloid-PET, CSF and the risk of progression to AD dementia.
Anne Fagan PhD, Washington University, Saint Louis, Missouri.

Communication 3: Total Aβ42 to total Aβ40 as a biomarker of cortical amyloid burden in subjects with subjective memory complaints.
Agustín Ruiz MD PhD. Research Director, Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades. Universitat Internacional de Catalunya (UIC), Barcelona, Spain.
8.30 - 10.00 a.m. Oral communications

8.30 - 8.45 a.m. OC15 - Cocoa supplement and multivitamin outcomes study of cognitive function (cosmos-mind): design of a large randomized clinical trial
Laura D. Baker, PhD1, Marti A. Espeland, PhD1, Stephen R. Rapp, PhD1, Sally A. Shumaker, PhD1, Sarah A, Gaussian, MS1, Howard D. Sesso, ScD1, JoAnn E. Manson, MD, DrPH2
1Wake Forest School of Medicine, Winston-Salem, USA, 2Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

8.45 - 9.00 a.m. OC16 - Rationale and design of a prospective, randomized, double-blind, dose-comparison safety and tolerability study of GRF6019 in mild-to-moderate Alzheimer’s disease
Jonas Hannestad, MD PhD1, Ian Gallager, PhD1, Katie Koborsi, MS1, S. Sakura Minami, PhD1, Darby Stephens, MBA1, Vittoria Kheifets, PhD1, Steven Braithwaite, PhD1
1Alkahest, Inc., San Carlos, USA

9.00 - 9.15 a.m. OC17 - Machine learning algorithm helps identify non-diagnosed prodromal Alzheimer’s disease patients in general population
Olga Uspehskaya-Cadoz1, Chaitanya Alamuri1, Sam Khinda1, Yuliya Nigmatullina2, Carolina Rubel1, Lanhui Wang1, Mengting Yang1, Tao Cao1, Nithil Kaly1
1IQVIA CNS Center of Excellence, 2IQVIA Analytics Center of Excellence, 3IQVIA Project Leadership

9.15 - 9.30 a.m. OC18 - ABBV-8E12, a humanized anti-tau monoclonal antibody, for treating early Alzheimer’s disease: Updated design and baseline characteristics of phase 2 study
Hana Florian, MD1, Steven E. Arnold, MD1, Randall J. Bateman, MD1, Joel B. Braunstein, MD, MBA2, Kumar Budur, MD1, Diana R. Kerwin, MD1, Holly Soares, PhD1, Delli Wang, PhD1, David M. Holtzman, MD1
1AbbVie, Inc., North Chicago, IL, USA, 2Massachusetts General Hospital, Boston, MA, USA

9.30 - 9.45 a.m. OC19 - Assessment of clinical meaningfulness of endpoints in the Generation Program by the Insights to Model Alzheimer’s Progression in real life (IMAP) study
A. Graf1, V. Risson1, S. Tzivelekis2, A. Gustavsson1, V. Bezyat1, A. Caputo1, P.N. Tariot1, J.B. Langbaum1, C. Lopez Lopez1, V. Viglietta1
1Novartis Pharma AG, 2Amgen, Inc., 3Quantify Research, 4Banner Alzheimer’s Institute

9.45 - 10.00 a.m. OC20 - Characterizing clinical severity among biomarker positive individuals: Applying the 2018 NIA-AA research criteria for Alzheimer’s disease to four large study cohorts.
Roos J. Jutten, MSc1, Rebecca E. Amariglio, PhD2,3, Gad A. Marshall, MD, PhD2,3, Dorene M. Rentz, PhD2,3, Wiesje M. Van der Flier, MD, PhD2,3, Keith A. Johnson2,4, Reisa A. Sperling, MD2,3, PhD, Sietske A.M. Slikkes, PhD2,3, Kathryn V. Papp, PhD2,3
1Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands, 2Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston MA, USA, 3Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA

10.00 - 10.30 a.m. Coffee break and poster session

10.30 - 11.00 a.m. Keynote 3
Anti-Tau treatments: Potential, challenges, and progress
Lennart Mucke, MD Director of the Gladstone Institute of Neurological Disease and Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco (UCSF), USA
Friday, October 26

Late Breaking communications

11.00 - 11.30 p.m.

**LB5 - 18F-AV-1451-A16: A clinico-pathological study of the correspondence between flortaucipir PET imaging and post-mortem assessment of tau pathology**

Mark A. Mintun1, Adam S. Fleisher1, Michael D. Devous2, Ming Lu2, Anupa K. Arora2, Thomas G. Beach3, Thomas J. Montine2, Michael J. Pontecorvo6

Eli Lilly and Company, Indianapolis, IN, USA, 2Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA, 3Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Phoenix, AZ, USA, 4Department of Pathology, Stanford University, Stanford, CA, USA

11.30 - 12.30 p.m.

**Symposium 5**

Towards the Development of a Complete Solution for Patients with Alzheimer’s Disease (AD)

**Moderator:** Rachelle Doody, MD, PhD1,2

1Genentech, Inc., South San Francisco, CA, USA, 2F. Hoffmann-La Roche Ltd, Basel, Switzerland

**Communication 1:** Self-detection of cognitive problems: benefits and challenges of online and digital tools

Mary Sano, PhD1,2

1Director, Alzheimer’s Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, 2Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

**Communication 2:** Enhancing earlier and more reliable diagnosis of AD through the use of emerging biomarkers

Christopher van Dyck, MD1,4

1Alzheimer’s Disease Research Unit, Yale University School of Medicine, New Haven, CT, USA, 2Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA, 3Department of Neuroscience, Yale University School of Medicine, New Haven, CT, USA, 4Department of Neurology, Yale University School of Medicine, New Haven, CT, USA

**Communication 3:** Moving towards combination therapies for disease modification in AD

Dennis J. Selkoe, MD1,2

1Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Boston, MA, USA, 2Harvard Medical School, Boston, MA, USA

Lunch and poster session

12.30 - 13.00 p.m.

Oral communications

13.00 - 2.45 p.m.

**OC21 - Extension and validation of an amyloid staging model: Associations with clinical measures**

Lyduine Collij, MSC1, Fiona Heeman, MSc1, Gemma Salvadó Blasco, MSc2, Elles Konijnenberg, MD, MSc3, Anoult den Braber, PhD4, Maqsood Yaqub, PhD5, Pieter Jelle Visser, MD, PhD6, Alie Mei Je Winb, Dr., PhD6, Philip Scheltens, MD, PhD7, Ronald Boellaard, PhD8, Bart N.M. van Berckel, PhD1, Jort Domingo Gispert López, PhD9, Mark Schmidt, MD, PhD5, Frederik Barkhof, MD, PhD10, Isadora Lopes Alves, PhD11

1Dept. of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, 2BarcelonaBeta Brain Research Center, Barcelona, Spain, 3Alzheimer Center and Dept. of Neurology, VU University Medical Center, Amsterdam, The Netherlands, 4Dept. of Biological Psychology, VU University Amsterdam, The Netherlands, 5Janssen Pharmaceutica, Beerse, Belgium, 6Institute of Neurology and Healthcare Engineering, University College London, London, United Kingdom

**OC22 - Twenty-four-month amyloid PET results of the gantenerumab high-dose SCarlet and Marguerite RoAD open-label extension studies**

Gregory Klein, PhD, Paul Delmar, PhD, Carsten Hofmann, PhD, Danielle Abi-Saab, PsyD, Mirjana Andjelkovic, PhD, Smiljana Ristic, MD, Nicola Voyle, PhD, Jacob Hesterman, PhD, John Seibyl, Ken Marek, Ferenc Martenyi, MD, Monika Baudler, PhD, Paulo Fontoura, MD, PhD, Rachelle Doody, MD, PhD

1Roche Pharma Research and Early Development, Basel, Switzerland, 2Roche / Genentech Product Development, Neuroscience, Basel, Switzerland, 3Roche Products Ltd, Welwyn Garden City, UK, 4Invicro, LLC, Boston, MA, USA
Friday, October 26

2.00 - 2.15 p.m.  OC23 - Multi-domain interventions to prevent dementia: from FINGER to World-Wide FINGERS
Mia Kivipelto1,2, On behalf of the World-Wide FINGERS network
1Karolinska Institute, Department of Clinical Geriatrics, Center for Alzheimer Research, Stockholm, Sweden, 2University of Eastern Finland, Institute of Clinical Medicine/Neurology, Kuopio, Finland

2.15 - 2.30 p.m.  OC24 - Identifying risk of cognitive decline in Mild Cognitive Impairment for population enrichment of clinical trials
Christian Dansereau1, PhD, Maor Zaltzhendler1, MEng, Angela Tam2,3, MSc, Pedro Rosa-Neto3, MD, PhD, Serge Gauthier4, MD, Pierre Bellec2,4, PhD
1Perceiv Research Inc., Montreal, CAN, 2Centre de Recherche de l’Institut Universitaire de Gériatrie de Montréal, CAN, 3Douglas Mental Health University Institute, McGill University, CAN, 4Department of Computer Science and Operations Research, University of Montreal, CAN

2.30 - 2.45 p.m.  OC25 - Study update on XanADu: Phase II study of XanamemTM in subjects with mild dementia due to Alzheimer’s disease
Craig Ritchie, MD, PhD, Centre for Dementia Prevention, University of Edinburgh, UK

Late Breaking communications

2.45 - 4.00 p.m.

2.45 - 3.00 p.m.  LB6 - Age and ApoE genotype-specific population frequencies of cerebral β-amyloidosis and hippocampal atrophy among cognitively normal individuals in CHARIOT-PRO
Hany Rofael, MD, PhD, Gerald Novak MD1, Luc Bracoud MSc1, Nandini Raghavan PhD1, Iad Saad PhD1, S Einstein MS1, Robert Brashers1, David Scott PhD1, Joel Schaerer PhD1, Celeste de Jager PhD1, Chi Udesh-Momoh, PhD1, the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and Leftfos Middleton MD1

3.00 - 3.15 p.m.  LB7 - Safety and efficacy results from the phase 3, multicenter, 18-month STEADFAST trial of azeliragon in participants with mild Alzheimer’s disease
Mawan Sabbagh, MD, Imogene Dunn, PhD1, Ann Gooch, PhD2, Tom Soeder, MS3, Karl Kieburtz, MD, MPH4, Carmen Valcarce, PhD5, Larry D Altstiel, MD, PhD6, Aaron H Burstein, PharmD2
1Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, 2vTv Therapeutics LLC, High Point, NC, USA, 3Cato Research LTD, Durham, NC, USA, 4Clinirex LLC, Longboat Key, FL, USA

3.15 - 3.30 p.m.  LB8 - Aducanumab titration dosing regimen: 36-month analyses from PRIME, a Phase 1b study in patients with early Alzheimer’s disease
Samantha Budd Haeberlein1, Carmen Castrillo-Viguera, MD1, Tianie Chen, PhD1, John O’Gorman, PhD1, Raj Rajagovindan, PhD1, Dathshaben Patel, PhD1, Philipp von Rosenstiel, MD1, Guanfang Wang, PhD1, Spyros Chalkias, MD1, LeAnne Shordos PharmD1, Claudia Prada, MD1, Christoph Hoch, MD1, Roger M Nitsch, MD1, Alfred Sandrock, MD, PhD1
1Biogen, Cambridge, MA, USA, 2Biogen, Maidenhead, UK, 3Anavex Life Sciences Corp., New York, NY

3.30 - 3.45 p.m.  LB9 - Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers
Harald Hampel, MD, PhD1, Mohammad Afshar, MD, PhD2, Frédéric Parmentier, PhD2, Coralie Williams, MSc2, Adrien Etcheto, MSc2, Federico Goodsaid, PhD3, Christopher U Missling, PhD4
1Department of Neurology, Sorbonne University, Paris, France, 2Ariana Pharma, Paris, France, 3Regulatory Pathfinders LLC, San Francisco, CA, 4Anavex Life Sciences Corp, New York, NY

3.45 - 4.00 p.m.  LB10 - Predictive performance of CSF and imaging AD biomarkers in ADNII/GO/2 MCI participants using the NIA-AA research framework
Leslie M Shaw, PhD1, Michal Figurski, PhD1, Susan Landau, PhD1, William Jagust, MD1, Clifford R Jack, MD1, Paul S Aisen, MD1, Ronald C Petersen, MD1, Michael W Weiner, MD1, John Q Trojanowski, MD, PhD1
1University of Pennsylvania, Philadelphia, USA, 2University of California, Berkeley, Berkeley, USA, 3 Mayo Clinic, Rochester, USA, 4University of Southern California, San Diego, USA, 5University of California, San Francisco, San Francisco, USA
Friday, October 26

4.00 - 4.30 p.m. Coffee break and poster session

4.30 - 5.00 p.m. Keynote 4
Combination therapy in AD
Daniel M. Skovronsky, MD, PhD - Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA

5.00 - 6.00 p.m. Symposium 6
Endpoints for early Alzheimer’s disease clinical trials: Interpretation and application of the draft FDA guidance
Symposium moderator: Eric Siemers, MD, Cogstate Ltd, New Haven, CT, USA

Communication 1: Clinical Endpoints in Stage 1, 2 and 3 Disease
Reisa Sperling, MD1, Ronald C. Petersen, MD, PhD2, Gary Romano, MD, PhD3, Paul Maruff, PhD4
1Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA, 2Department of Neurology, Mayo Clinic, Rochester, MN, USA, 3Janssen R&D, Titusville, NJ, USA, 4Cogstate Ltd, Melbourne, Victoria, Australia

Communication 2: Biomarkers in Stage 1, 2 and 3 Disease
Samantha Budd Haeberlein PhD1, Jose Luis Molinuevo, MD, PhD2, Christopher C. Rowe, PhD3, Maria C. Carrillo PhD4, Clifford R. Jack, Jr., MD5
1Biogen, Cambridge, MA, USA, 2BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation and Hospital Clinic-IDIBAPS, Barcelona, Spain, 3Department of Molecular Imaging, Austin Health, University of Melbourne, Melbourne, Australia, 4Alzheimer’s Association, Chicago, IL, USA, 5Department of Radiology, Mayo Clinic, Rochester, MN, USA

Communication 3: Approaches to Establishing the Meaningfulness of Treatment Effects
Chris J. Edgar, PhD1, George Vradenburg, JD2, Jason Hassenstab, PhD3
1Cogstate Ltd, London, UK, 2UsAgainstAlzheimer’s and Alzheimer’s Disease Patient and Caregiver Engagement (AD PACE), Chevy Chase, MD, USA, 3Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
8.30 - 9.15 a.m.

**Presentation and panel discussion:**

**AMBAR (Alzheimer’s Management By Albumin Replacement) Phase IIb/III Results**

Presentation by Antonio Páez MD, Grifols S.A, Barcelona, Spain

Followed by Panel Discussion with:

- Panel discussion moderator: Jeffrey L. Cummings, MD, ScD, Cleveland Clinic, Las Vegas, NV, USA
- Mercè Boada MD, PhD, Fundació ACE, Universitat Internacional de Catalunya, Barcelona, Spain
- Oscar L. Lopez MD, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- Zbigniew M. Szczepiorkowski, MD, PhD, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
- Bruno Vellas, MD, PhD, University Hospital, Toulouse, France

9.15 - 9.45 a.m.

**Keynote 5**

How BIG and GOOD Data are revolutionizing neurodegenerative disease research

Cristina Sampaio, MD, PhD - Chief Medical Officer, CHDI Foundation, Princeton, USA

9.45 - 10.15 a.m.

**Coffee break and poster session**

10.15 - 11.15 a.m.

**Oral communications**

10.15 - 10.30 a.m.

**OC26 - First longitudinal evaluation of the tau tracer [18F]MK-6240 for the use in clinical trials**

Tharick A. Pascoal MD, Sulantha Mathotaarachchi MSc, Mira Chamoun PhD, Joseph Therriault BSc, Robert Hopewell PhD, Gassan Massarweh PhD, Andrea L. Benedet, MSc, BSc, Min Su Kang, Jean-Paul Soucy MD, Serge Gauthier, MD, Pedro Rosa-Neto, PhD

1Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada,
2Montreal Neurological Institute, McGill University, Montreal, Canada

10.30 - 10.45 a.m.

**OC27 - Implementation of the NIA-AA research framework: toward a biological definition of Alzheimer’s disease in AIBL**

Samantha C Burnham 1,2, Preciosa M Coloma 1, Qiao-Xing Li, Steven Collins, Simon Laws, James Doecke, Paul Maruff, Ralph N Martins 29, David Ames 29, Christopher C Rowe 6, Colin L Masters 6, Victor L Villemagne 11

1eHealth, CSIRO, Parkville, VIC, Australia, 2School of Medical Sciences, Edith Cowan University, Joondalup, Australia, 3Product Development - Personalised Health Care - Data Science, F. Hoffmann-La Roche Ltd., Basel, Switzerland, 4The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia, 5Department of Pathology, University of Melbourne, Parkville, Australia, 6Macquarie University, Sydney, Australia, 7eHealth, CSIRO, Herston, QLD, Australia, 8Cogstate Ltd., Melbourne, Australia, 9Macquarie University, North Ryde, Australia, 10National Ageing Research Institute, Melbourne, Australia, 11Austin Health, Melbourne, Australia, Brain Health, Las Vegas, NV, USA

10.45 - 11.00 a.m.

**OC28 - The neuroprotective effect of a new photobiomodulation technique on Aβ25-35 peptide-induced toxicity dramatically impact gut microbiota dysbiosis**

Jacques Touchon, MD, PhD, Laura Auboyer, PhD, Johann Meunier, PhD, Laura Ceolin, PhD, François J. Roman, PhD, Rémy Burcelin, PhD, Guillaume J. Blivet, MS

1Montpellier University, France, 2INSERM U1061, Montpellier, France, 3REGENLIFE SAS, Montpellier, France, 4Amylgen SAS, Montfernier-sur-Lez, France, 5Vaiomer SAS, Labège, France
Disclosure of Alzheimer’s risk biomarkers to cognitively normal older adults

Communication 1: “Not just a colonoscopy” – cognitively normal older adults reactions to learning an amyloid PET result
Jason Karlawish, MD1, Kristin Harkins, MPH2, Emily Largent, JD, PhD3, Pamela Sankar, PhD3, Jeff Burns, MD4, David Sulzer, MD5, Joshua Grill, PhD6
1Departments of Medicine, Medical Ethics and Health Policy, and Neurology, University of Pennsylvania, Philadelphia, PA, USA, 2Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 3Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA, 4Department of Neurology, University of Kansas, Kansas City, KS, USA, 5Department of Psychiatry, University of California, Los Angeles, CA, USA, 6Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA

Communication 2: Remote genetic counseling and disclosure of APOE genotype within the Generation study
Elisabeth McCarty Wood, MS1, Cara Cacioppo, MS1, Neeraja Reddy, MS2, Dare Henry-Moss, MPH1, Demetrios Ofidis, BS1, Brian L. Egleston, PhD1, Jason Karlawish, MD1, Scott Roberts, PhD1, Scott Kim, MD, PhD1, Carolyn Langlois, MA6, Eric M. Reiman, MD1, Pierre B. weekend, PhD6, Angela R. Bradbury, MD1
1University of Pennsylvania, Philadelphia, PA, USA, 2Mapmygenome, Navi Mumbai, India, 3Fox Chase Cancer Center, Philadelphia, PA, USA, 4University of Michigan, Ann Arbor, MI, USA, 5National Institutes of Health, Bethesda, MD, USA, 6Banner Alzheimer’s Institute, Phoenix, AZ, USA

Communication 3: Application of an APOE disclosure model at a clinical trial site and the impact of dual disclosure of amyloid PET results
Louisa Thompson, PhD1,2, Athene Lee, PhD1,2, Meghan Collier, PhD1,2, Danielle Goldfarb, MD1,2, Brittany Dawson, FNP2, Stephen Salloway, MD3,4, Jessica Alber, PhD1,2
1Warren Alpert Medical School of Brown University, Providence, RI, USA, 2Butler Hospital, Providence, RI, USA

Lunch and poster session

Oral communications

OC30 - Cost-effective, multi-step enrichment strategy for clinical trials using Artificial Intelligence
Sulantha Mathotaarachchi MSc1, Tharick A. Pascoal MD1, Mira Chamoun PhD1, Andrea L. Benedet MSc1, Min Su Kang BSc1, Joseph Therriault BSc1, Serge Gauthier MD1, Pedro Rosa-Neto MD1, PhD1
1McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada

OC31 - TRC-PAD: Accelerating participant recruitment in AD clinical trials through innovation
Gustavo A. Jimenez-Maggiora, MBA1, Rema Raman, PhD1, Michael S. Rafii, MD, PhD1, Reisa Anne Sperling, MD1, Jeffrey Lee Cummings, MD1, Paul S. Aisen, MD1
1Alzheimer’s Therapeutics Research Institute, University of Southern California, San Diego, CA, USA, 2Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, 3Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, 4Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
Saturday, October 27

1.45 - 2.00 p.m.  **OC32 - Detecting brain amyloid status using fully automated plasma Aβ biomarker assays**  
Sebastian Palmqvist, Shorena Janelidze, Erik Stromrud, MD PhD, Henrik Zetterberg, MD PhD, Johann Karl, MD PhD, Niklas Mattsson, MD PhD, Kaj Blennow, MD PhD, Udo Eichenlaub, MD PhD, Oskar Hansson, MD PhD  
Clinical Memory Research Unit, Lund University, Sweden; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Sweden; Roche Diagnostics GmbH, Penzberg, Germany

2.00 - 2.15 p.m.  **OC33 - Concordance of florbetapir (18F) PET and Elecsys® β-Amyloid(1-42) CSF immunoassay in the CREAD (BN29552) study of crenozumab in prodromal-to-mild AD**  
Timo Grimm, MD, Christina Rabe, PhD, Mercidita Navarro, PhD, David Clayton, PhD, Ekaterina Manuilova, MSc, Udo Eichenlaub, PhD, Jillian Smith, BSc, Susanne Ostrowitzki, MD, PhD, Lee Honigberg, PhD, Tobias Bittner, PhD  
Department of Psychiatry, Klinikum reichs der Isar, Technical University of Munich, Munich, Germany; Genentech, Inc., South San Francisco, CA, USA; Roche Diagnostics GmbH, Penzberg, Germany; Roche Products Ltd., Welwyn Garden City, UK; Hoffmann-La Roche Ltd., Basel, Switzerland

2.15 - 2.30 p.m.  **OC34 - Development of Aβ, tau and cognitive changes during the time course of sporadic Alzheimer’s disease**  
Niklas Mattsson, MD PhD, Oskar Hansson, MD PhD, Michael W. Weiner, MD PhD, Philip S. Insel, MS PhD  
Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden; Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA

2.30 - 2.45 p.m.  **OC35 - U.S. POINTER: Study design and trial hitch-off**  
Laura Baker, Ph.D.; Mark Espeland, Ph.D.; Miia Kivipelto, M.D., Ph.D., Gustavo Jimenez-Maggiora, MBA, Martha Clare Morris, Sc.D., Rema Raman, Ph.D., Scott Rushing, M.D., Jeffrey Whitney, M.D., Rachel Whitmer, Ph.D., Nancy Woolard  
Wake Forest School of Medicine On Behalf of the U.S. POINTER Study Team

2.45 - 3.00 p.m.  **OC36 - Implications for AD clinical trials and opportunities to leverage the first Alzheimer’s association U.S. National Best Clinical Practice Guidelines for the evaluation of cognitive behavioral syndromes, Alzheimer’s disease and related conditions**  
Alireza Atri, MD/PhD, Mary Norman, MD, David S. Knopman, MD, Michael W. Weiner, MD, Mary Sano, Ph.D., Carolyn Clevenger, DNP, Chiadi U Onyike, MD, MPH, Susan Scaland, MSN, CRNP, GNPC, Paige Lin, PhD, James Hendrix, PhD, Maria C. Carrillo, Ph.D., Brad C. Dickerson, MD and Alzheimer’s Association Best Clinical Practices Workgroup  
Banner Sun Health Research Institute/Banner Health, Sun City, AZ, USA; Center for Brain/Mind Medicine, Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA; Envision Living, Dallas, TX, USA; Mayo Clinic, Rochester, MN, USA; University of Pennsylvania, Philadelphia, PA, USA; James J. Peters VA Medical Center, New York, NY, USA; Emory University, Atlanta, GA, USA; Johns Hopkins University, Baltimore, MD, USA; Dementia Connection, Clark Summit, PA, USA; Tufts Medical Center, Boston, MA, USA; Alzheimer’s Association, Chicago, IL, USA; Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, USA

3.00 - 3.15 p.m.  **OC37 - Pros and cons of AD composite endpoints considering recently revised regulatory guidance and 2018 NIA-AA research framework**  
Michael T. Ropacki, PhD, Suzanne Hendrix, PhD  
Strategic Global Research & Development, Half Moon Bay, USA; Pentara Corporation, Salt Lake City, USA

3.15 - 3.30 p.m.  **OC38 - AD therapeutics: What would it mean to physicians and patients if multiple options are available?**  
Nick Fox, MD, PhD, Dementia Research Centre, UCL, London, UK

3.30 - 3.45 p.m.  **OC39 - The European Prevention of Alzheimer’s Dementia (EPAD); Summary of First Formal Data Lock (EPAD V500.0) and predictors of amyloid status**  
Craig Ritchie, MD, PhD, Centre for Dementia Prevention, University of Edinburgh UK

3.45 p.m.  **End of conference**
Theme 1. Clinical trials: Methodology
P21, P45, P54, P59, P61, P82, P86, P90, P91-P101 and LBP1 to LBP12

Theme 2. Clinical trials: Results
P7, P12, P13, P15-P18, P36, P80, P109-P112 and LBP13 to LBP21

Theme 3. Clinical trials: Imaging
P10, P35, P62, P76, P113-P124 and LBP21 to LBP24

Theme 4. Clinical trials: Biomarkers including plasma
P1, P4, P22, P28, P30, P39, P44, P57, P64-P66, P73, P78, P81, P125-P130
and LBP25 to LBP40

Theme 5. Clinical trials: Cognitive and functional endpoints
P2-P3, P8-P9, P19, P25-P27, P53, P67, P69, P71, P74, P77, P83, P140-P144,
PP146-149 and LBP41 to LBP46

Theme 6. Cognitive assessment and clinical trials
P6, P14, P24, P29, P33-P34, P41-P42, P47-P52, P55, P63, P68, P70, P72,
P75, P87-P89, P151-P159, P162 and LBP47 to LBP52

Theme 7. Behavioral disorders and clinical trials
P32, P37, P43, P163 and LBP53

Theme 8. Health economics and clinical trials
P17, P40, P58, P164

Theme 9. Epidemiology and clinical trials
P17, P38, P46, P165-P168 and LBP54 to LBP56

Theme 10. Clinical Trials: Animal Models
PIO2-PIO4 and LBP57 to LBP58

Theme 11. New therapies and clinical trials
P5, P11, P20, P23, P56, P60, P79, P84-P85, P105-P108 and LBP59 to LBP62
Theme 1. Clinical trials: Methodology

P21 - Patterns of MMSE subtest scores in amyloid-positive and -negative participants in J-ADNI
Ryooho Ihara, MD1, Kazushi Suzuki, MD1, Atsushi Iwata, MD1, Takeshi Iwatsubo, MD2,3, the Japanese Alzheimer’s Disease Neuroimaging Initiative
1The Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo, Japan; 2Department of Neurology, The University of Tokyo, Tokyo, Japan; 3Department of Neurology, The University of Tokyo, Tokyo, Japan

P45 - Innovations in care community-based recruitment to clinical trial research
Jacobo Mintzer, MD, MBA1, Mike Splaine2, Erin Bech, MPH3
1Research and Innovation Center, Roper St. Francis, Charleston, SC, USA; Managing Partner, Recruitment, Partners LLC, Columbia, MD, USA, 2Managing Partner, Recruitment Partners LLC, Columbia, MD, USA, 3Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P54 - Validation of Alzheimer’s biomarkers: β-amyloid I-42 and total tau in CSF by automated CLEIA on lumipulse g 1200 platform
Satya Nandana Narla1, Amanda Dider1, Ming Hu1, Tina LV1, Yuan Xueling2 and Martine Florent3
1Immunology Department, Covance Central Laboratories, Indianapolis, USA, 2Immunology Department, Covance Central Laboratories, Shanghai, China

P59 - The impact of frailty on the risk of screen failure in randomized controlled trials on Alzheimer’s disease
Alessandro Trebbastoni, MD, PhD1, Marco Canevelli, MD, PhD1, Giuseppe Bruno, MD1, Carlo de Lena, MD1, Letizia Imbriani1, Fabrizia D’Antonio, MD1, Laura Pieroni1
1Department of Human Neuroscience, «Sapienza» University of Rome, Italy

P61 - Concierge site services: site-specific support and capacity development improves recruitment performance
Jacobo Mintzer, MD, MBA1, Mike Splaine2, Erin Bech, MPH3
1Research and Innovation Center, Roper St. Francis, Charleston, SC, USA, Managing Partner, Recruitment Partners LLC, Columbia, MD, USA, 2Managing Partner, Recruitment Partners LLC, Columbia, MD, USA, 3Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P82 - Meotis3rc: Efficient network for clinical research on cognitive disorders in North and Pas-de-Calais
Catherine Adnet-Bonte1, MD, Brigitte Leprince1, Laetitia Breuilh, PhD1,2, Florence Pasquier, MD, PhD1,2
1Meotis, Centre Hospitalier Universitaire de Lille, France, 2Neurology Department, Centre Hospitalier Universitaire de Lille, France, 3Excellence Laboratory DISTALZ, Inserm UMR17, Univ Lille

P86 - Recruiting older Latinos in senior centers with a culturally tailored Alzheimer’s presentation
Jaime Perales1, PhD1, MPH; W Todd Moore, MS1, Mariana Ramirez, LMSW2; Linda Lara, BA2; Erica Davis, BA2; Jason Resendez, MS4; Eric D Vidoni, PhD5
1University of Kansas Medical Center, Kansas-USA, 2Cuadalupe Center, Kansas City-USA, 3Don Bosco Senior Center, Kansas City-USA, 4Latinos Against Alzheimer’s Coalition, Chevy Chase-USA/177, Univ Lille

P90 - REVERSE-SD: ongoing phase-2b study of neflamapimod designed in accordance with emerging scientific and regulatory concepts of early Alzheimer’s disease (AD)
John Alam1, Kelly Blachburn1, Niels Prins2,3, Philip Schelten2
1EIP Pharma Inc., Cambridge, MA, USA, 2ClinCloud, Orlando, FL, USA, 3Anavex Life Sciences Corp., New York, USA

P91 - The impact of frailty on the risk of screen failure in randomized controlled trials on Alzheimer’s disease
Stephen Macfarlane, MBBS FRANZCP1, Michael Kornhauser BPharm1, Ella Modini BSc1, Harald Hampel, MD PhD2, Stephan Toutain MS3, Tina LV4
1Research and Innovation Center, Roper St. Francis, Charleston, SC, USA; Managing Partner, Recruitment Partners LLC, Columbia, MD, USA,, 2Managing Partner, Recruitment Partners LLC, Columbia, MD, USA, 3Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P92 - Impact of genetic testing on clinical trial participation and subject selection, a pilot study
Mareike Cajal-Berman1, PhD1, Jessica Branning2, Vishnuharaith Nitta, MS2
1Bioclinica Research, Orlando, FL, USA, 2ClinCloud, Orlando, FL, USA

P93 - The impact of Transcranial Magnetic Stimulation on diagnostic confidence in patients with Alzheimer Disease eligible for clinical trials
Alberto Benussi, MD1, Antonella Alberici, MD1, Clarissa Ferrari, MD1, Valentina Cantoni, MS1, Valentina Dell’era, MD1, Rosanna Turrone, MS1, Maria Sofia Cotelli, MD1, Giuliano Binetti, MD1, Barbara Paghera, MD1, Giacomo Koch, MD1, Barbara Bonanni, MD1, Alessandro Padovani, MD, PhD1
1Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, 2IFCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, 3Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy, 4Neurology Unit, Ospedale Vallecamonica, Esine, Brescia, Italy, 5Non Invasive Brain Stimulation Unit, IFCCT Santa Lucia Foundation, Rome, Italy, 6Stroke Unit, PoliClinico T. Vergata, Rome, Italy
P94 - Applying patient-centred insights to optimize protocol design and increase biomarker collection acceptability in AD trails
Kenneth Stanley¹, Carolina Rubel¹, Lynne Hughes¹
¹IQVIA Project Leadership Unit

P95 - CSF biomarkers outcomes in the ETHERAL AD study
Harald Hampe³,⁴, Carlos Buesa¹, Tamara Maes³, Mabel Arevalo³, Michele Lufino³, Roger Bullock⁵
³AXA Research Fund & Sarbonne University Chair, Paris, France, ²Sarbonne University, UCR, n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitie-Salpetriere Hospital, Paris, France, ³Brain & Spine Institute (ICM), INSERM U1127, CNRS UMR 7225Paris, France, ⁴Institute of Memory and Alzheimer’s Disease (IM2A), Department of Neurology, Pitie-Salpetriere Hospital, AP-HP, Paris, France, ⁵Oryzon Genomics SA, Barcelona, Spain

P96 - EMIF-AD: A unique pan-European platform for large-scale research on biomarkers and risk factors for Alzheimer’s Disease
Preciosa M Coloma¹, Stephanie J. B. Vos¹, Isabelle Bos², Andy Simmons³, Rih Vandenberghe⁴, Philip Scheltens⁵, Jose Luis Molinuevo⁶,⁷, Flavio Nobili², Sebastián Angelborghp³,⁴, Giovanni Frisoni³,⁴, Gaël Chetelat³, Alberto Lleó³, Anders Wallim³, Julius Popp³,⁴, Pablo Martinez-Lage⁷, Gonzalo Duran-Pacheco¹, Pieter Jelle Visser⁵,⁶, Mark F Gordon⁷, Gerald Novák⁸
¹Personalised Health Care, Data Science, F. Hoffmann-La Roche AG, Basel, Switzerland, ²Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands, ³Institute of Psychiatry, Kings College, London, UK, ⁴University Hospital Leuven, Leuven, Belgium, ⁵Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands, ⁶Alzheimer’s disease & other cognitive disorders unit, Hospital Clinic-IDIBAPS, Barcelona, Spain, ⁷Barcelona Beta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain, ⁸Clinical Neurology, Department of Neurosciences (DINOCM), University of C ener and IRCCS Polyclinic San Matteo Hospital, Genoa, Italy, ⁹Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hage Beuken, Antwerp, Belgium, ¹⁰Reference Center for Biological Markers of Dementia (BROADEM), Institute Bom-Bunge, University of Antwerp, Antwerp, Belgium, ¹¹University of Geneva, Geneva, Switzerland, ¹²IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, ¹³Inserm, Inserm UMR-S U1237 Université de Caen-Normandie, GIP Cyceron, Caen, France, ¹⁴Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁵University of Gothenburg, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Section for Psychiatry and Neurochemistry, Gothenburg, Sweden, ¹⁶Geriatric Psychiatry, Department of Mental Health and Psychiatry, Geneva University Hospitals, Switzerland, ¹⁷Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland, ¹⁸CITA-Alzheimer Foundation, San Sebastian, Spain, ¹⁹Teva Pharmaceuticals, Malvern, PA, USA, ²⁰Janssen Pharmaceutical Research and Development, Titusville, NJ, USA

P97 - Using transcription phenotypes to utilise basket trial methodology from oncology to create new targets in CNS disorders
Roger Bullock¹, David Rotllant², Michele Lufino², Cristina Mascaro², Carlos Buesa², Tamara Maes², Sonia Gutierrez², Marta Valverde¹, Tony Ramos³
¹Oryzon Genomics, Barcelona, Spain, ²Vall D’Hebron Hospital, Barcelona, Spain, ³Teva Pharmaceuticals, Malvern, PA, USA, ⁴Janssen Pharmaceutical Research and Development, Titusville, NJ, USA

P98 - Can online registers with small amounts of phenotypic data reduce screen failure rates in Alzheimer’s disease trials?
Piens Kotting¹, MBA¹, Kris Beicher², Adam Smith³, Clare Shaw, PhD²
¹University of Exeter Medical School, Exeter, UK, ²University of Leeds, Leeds, UK, ³Institute of Neurology, University College London, London, UK

P99 - Trial design of the GRADUATE studies: Phase III, randomized, placebo-controlled studies evaluating gantenerumab in patients with early Alzheimer’s disease
Smiljana Ristic¹, Mercer Boada², MD, PhD², Nathalie Pross, PhD², Danielle Abi-Saab, PsyD², Szofia Bullain², MD², Mirjana Andjelkovic, PhD², Paul Delmar, PhD², Carsten Hofmann, PhD², Alison Searle, BSc³, Monika Baudler, PhD², Paulo Fontoura, MD, PhD², Rachelle Doody, MD, PhD⁴
¹Oryzon Genomics, Barcelona, Spain, ²Vall D’Hebron Hospital, Barcelona, Spain, ³Teva Pharmaceuticals, Malvern, PA, USA, ⁴Janssen Pharmaceutical Research and Development, Titusville, NJ, USA

P100 - Personalised Health Care, Data Science, F. Hoffmann-La Roche AG, Basel, Switzerland, ²Sarbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitie-Salpetriere Hospital, Paris, France, ³Institute of Psychiatry, Kings College, London, UK, ⁴University Hospital Leuven, Leuven, Belgium, ⁵Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands, ⁶Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands, ⁷Institute of Psychiatry, Kings College, London, UK, ⁸University Hospital Leuven, Leuven, Belgium, ⁹Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hage Beuken, Antwerp, Belgium, ¹⁰Reference Center for Biological Markers of Dementia (BROADEM), Institute Bom-Bunge, University of Antwerp, Antwerp, Belgium, ¹¹University of Geneva, Geneva, Switzerland, ¹²IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, ¹³Inserm, Inserm UMR-S U1237 Université de Caen-Normandie, GIP Cyceron, Caen, France, ¹⁴Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁵University of Gothenburg, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Section for Psychiatry and Neurochemistry, Gothenburg, Sweden, ¹⁶Geriatric Psychiatry, Department of Mental Health and Psychiatry, Geneva University Hospitals, Switzerland, ¹⁷Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland, ¹⁸CITA-Alzheimer Foundation, San Sebastian, Spain, ¹⁹Teva Pharmaceuticals, Malvern, PA, USA, ²⁰Janssen Pharmaceutical Research and Development, Titusville, NJ, USA

P101 - Study enrollment and Alzheimer’s disease pathology in relation to cohort type and participant characteristics in the EPAD Registry
Lisa Vermunt¹, MD¹, Graciela Muniz-Terrera, PhD²,³, Lea ter Meulen, MSc¹, Colin Veal, PhD¹, José Luis Molinuevo, MD, PhD¹, Pierre-Jean Ousset, MD², Niels D Prins, MD, PhD², David Porteous, PhD², Craig W Ritchie, PhD², Philip Scheltens, MD, PhD¹, Gerald Luscan, MSc², Anthony J Brookes, PhD², Pieter Jelle Visser, MD, PhD²
¹VU University Medical Center, Amsterdam, Netherlands, ²University of Edinburgh, Edinburgh, Scotland, ³University of Victoria, Victoria, Canada, ⁴University of Cambridge, Cambridge, England, ⁵University of Leicester, Leicester, England, ⁶Barcelona Betoresearch Center, Barcelona, Spain, ⁷Clinic University Hospital, Barcelona, Spain, ⁸CHU Toulouse, Gerontopôle and INSERM UMR 1027, Toulouse, France, ⁹Brain Research Center, Amsterdam, Netherlands, ¹⁰Pfizer, Paris, France, ¹¹Maasricht University, Maastricht, Netherlands

P102 - The effects of participant characteristics and selection criteria on Alzheimer disease clinical trial outcomes
Richard E. Kennedy, MD, PhD¹, Guoqiao Wang, PhD¹, Mackenzie E. Fowler, MPH², Gary R. Cutter, PhD², Lon S. Schneider, MD, MS²
¹Department of Medicine, University of Alabama at Birmingham, USA, ²Division of Biostatistics, Washington University, St. Louis, USA, ³Department of Epidemiology, University of Alabama at Birmingham, USA, ⁴Department of Biostatistics, University of Alabama at Birmingham, USA, ⁵Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, USA
Late Breaking Posters

LBP1 - Harnessing the power of big data and technology innovations to advance Alzheimer’s disease clinical development
Olga Uspenskaya-Cadoz, Yuliya Nigmatullina, Kenneth Stanley, Chaitanya Alamuri, Penny Randall, Sam Khinda, Lanhuai Wang, Mengting Yang, Carolina Rubel, Lynne Hughes, Tao Cao, Michelle O’Keefe, Nikhil Kayal
IQVIA CNS Center of Excellence, IQVIA Analytics Center of Excellence, IQVIA Project Leadership

LBP2 - Course correction in A4: implementation of dose escalation
Karen Holdridge, MPH, Roy Yaari, MD, Brian A. Willis, PhD, Isabella Velona, MS, Paul Aisen, MD, Reisa Sperling, MD
Eli Lilly and Company, Indianapolis, USA, University of Southern California, San Diego, USA, Brigham and Women’s Hospital, Boston, USA

LBP3 - Dose escalation in the DIAN-TU solanezumab arm. Was solanezumab in mild to moderate AD dementia too little, too late?
Karen Holdridge, MPH, Roy Yaari, MD, Brian A. Willis, PhD, Isabella Velona, MS, Susan Mills, Randall Bateman
Eli Lilly and Company, Indianapolis, USA, Washington University, Saint Louis, USA

LBP4 - Does the US have enough clinical trials sites to keep up with the demand of new chemical and device compounds entering the NDA?
Sean Stanton, Dan Davis, Vishnukartih Nitta, BS, Jessica Branning, BS, John Dwyer, JD, Jason Bork, MBA, James Taylor, and George Vradenburg, JD
LifeCore Solutions, LLC, ClinCloud, LLC, Global Alzheimer’s Platform, BioClinica Research, Independent Consultant, Caregiver

LBP5 - Goal Attainment Scaling scores, without defined attainment levels, were associated with standardized measures in people with vascular and mixed dementia
Kenneth Rockwood, Justin Stanley, Taylor Dunn, Susan E Howlett
DGI Clinical Inc., Halifax, NS, Canada, Dalhousie University, Halifax, NS Canada

LBP6 - Consultation for Alzheimer’s disease prevention: an effective recruitment strategy for preventive trials
Isabelle Carrie, PhD, Julien Delrieu, MD, Françoise Lala, MD, Christophe Hein, MD, Delphine Pennetier, PhD, Pierre Jean Ousset, MD, Bruno Vellas, MD, PhD
Gerontopole, Toulouse University Hospital, Toulouse, France, Inserm Unit 1027, Toulouse, France, University of Toulouse III, Toulouse, France

LBP7 - Finding a common baseline: Insights from latent disease-time progression modeling in Alzheimer’s disease
Lars Lau Raket
H Lundbeck A/S, Denmark

LBP8 - The use of Machine Learning algorithms in Clinical Trials on Alzheimer’s Disease
Deila A Gheorghe, MSc, Sarah Bauereimer, PhD, John Gallacher, PhD
University of Oxford, Department of Psychiatry, Oxford, UK

LBP9 - Predicting cerebral amyloid status and cognitive performance in cognitively normal adults
Alette Wessels, PhD, Adrian Schembrì, DPsych, Pav Kalinowski, PhD, Reisa Sperling, MD, Roy Yaari, MD, Paul Aisen, MD, David Barfield, MS, Scott Andersen, MS, John R. Sims, MD, A4 Study Team, Paul Maruff, PhD
Eli Lilly and Company, Indianapolis, IN, USA, Cogstate Ltd, New Haven, Connecticut, CT, USA, Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA, Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego

LBP10 - Novel patient identification and pre-screening model improves patient recruitment and retention and reduces screen-failure rates for AD clinical trials
Lucianne Dobson, PhD, Miguel Rosa Grilo MD, Catherine Mummery PhD, FRCP
Dementia Research Centre, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK

LBP11 - Delivery of a Patient Focused In-Trial Online Community in a Multi-Year Alzheimer’s Disease Study
Adam Butler, Denis Curtin, PhD, Mackenzie Johnson, and Jeff Lee
CRF, Brachet, Arlington, VA, USA

LBP12 - Multi-crossover randomized controlled trial designs in Alzheimer’s disease
Steven E. Arnold, MD, Rebecca A. Betensky, PhD
Massachusetts General Hospital and Harvard Medical School, Boston, USA, Harvard T.H. Chan School of Public Health, Boston, MA
Theme 2. Clinical trials: Results

P7 - Effects of vortioxetine on cognitive functions in patients with Alzheimer’s disease and depressive symptoms: interim results of an observational study

Eduardo Cumbo MD¹, Silvia Cumbo MD¹, Salvatore Torregrossa PsyD¹, Daniela Migliore PsyD¹

¹Neurodegenerative Disorders Unit, ASP, Caltanissetta, Caltanissetta (Italy)

P12 - Critical Path for Alzheimer’s Disease (CPAD) consortium’s vision for an aggregated, standardized, and actionable global Alzheimer disease clinical trial database

Volker D. Kern, PhD¹, Stephen P. Arneric, PhD¹, Maria C. Carrillo, PhD², James Hendrix, PhD², Billy Dunn, MD³, Stacie Weninger, PhD³, Jeffrey A. Kaye, MD⁴, Daniel R. Karlin, MD⁴, Lisa H. Gold, PhD⁴, Michael Gold, MD⁴, Samantha Budd Haeberlein, PhD⁴, Molly Shea, PhD⁵, George Vradenburg, Daniela J. Conrado, PhD⁵, and Klaus Romero, MS, MD⁵

¹Critical Path for Alzheimer’s Disease Consortium, Critical Path Institute, Tucson, AZ, USA, ²Alzheimer’s Association, Chicago, IL, USA, ³U.S. Food and Drug Administration, Silver Spring, MD, USA, ⁴Prime Biomedical Research Initiative, Cambridge, MA, USA, ⁵Oregon Health & Science University, Portland, OR, USA, ⁶Pfizer, Boston, MA, USA, ⁷Merck & Co., Inc., Kenilworth, NJ, USA, ⁸AbbVie, North Chicago, IL, USA, ⁹Biogen, Cambridge, MA, USA, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ¹¹UsAgainstAlzheimer’s, Washington, DC, USA

P13 - Effects of body weight on safety of 23mg donepezil in Alzheimer’s disease: A post-hoc analysis of a multicenter, randomized trial

Yun Jeong Hong, MD, PhD¹,², Hyun Jeong Han, MD, PhD ³, Young Chul Youn, MD, PhD⁴, Kyung Won Park, MD, PhD⁵, Dong Won Yang, MD, PhD⁶, Sang Yun Kim, MD, PhD⁷, Hwa Jung Kim, MD, PhD⁷, Ji Eun Kim, MD, PhD⁷, Jae-Hong Lee, MD, PhD⁷, the ODESA study group

¹Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, ²Biomedical research institute, Pusan National University Hospital, Pusan, ³Neurology, Dementia and Neurocognitive Center, Myongji Hospital, Seonam University College of Medicine, Ilsan, ⁴Neurology, Chung-Ang University Hospital, Seoul, ⁵Neurology, Dong-A University College of Medicine, Busan, ⁶Neurology, The Catholic University of Korea, Seoul, ⁷Neurology, Seoul National University Bundang Hospital, Seongnam, ⁸Preventive Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, ⁹Neurology, University of Ulsan College of Medicine, Gangneung Asan Medical Center, Gangneung, Korea

P15 - A single ascending dose study to assess the safety, pharmacokinetics, and pharmacodynamics of LY3303560, a tau-specific antibody, in healthy volunteers

Stephen Lowe¹, Jeffrey Dage¹, Ann Cleverley², Albert Lo², Elizabeth S. LaBell³, Hakop Gevorkyan⁴, Stanford Jhee⁵, Larry Huffman², Boris Calderon², Brian A. Willis²

¹Lilly Centre for Clinical Pharmacology, Singapore, ²Eli Lilly and Co, Indianapolis, IN, ³Eli Lilly and Co, Erl Wood, UK, ⁴California Clinical Trials Medical Group, Inc., ⁵PAREXEL Early Phase, Glendale, CA, USA

P16 - CNP520, a novel oral BACE1 inhibitor, has no clinically meaningful effect on QTc interval up to supratherapeutic doses

Stefan Viktor Vormfelde, MD/PhD¹, Nicole Pezous ¹, Gilbert Lefèvre, PhD¹, Carine Kolly, PhD¹, Ulf Neumann, PhD¹, Pierre Jordaan, MD², Guenter Heimann, PhD², Mike Ufer, MD/PhD², Ana Graf², Eric Legangneux, MD¹

¹Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland

P18 - Differences in treatment response between males and females with mild-moderate Alzheimer disease being treated with cholinesterase inhibitors

Kenneth Rockwood, MD¹,², Justin Stanley, BSc¹, Susan E Howlett, PhD¹,²,³

¹DCG Clinical Inc, Halifax, NS, Canada, ²Division of Geriatric Medicine, Dalhousie University, Halifax, NS Canada, ³Department of Pharmacology, Dalhousie University, Halifax, NS, Canada

P36 - Phase I Clinical Studies in Alzheimer’s Disease: Cerebrospinal Fluid Oligomer Change and Other Exploratory Outcomes of amyloid β Aggregate-Specific Antibody KHK6640

Marc Cantillon, MD¹, Hiroyuki Shimada, MD, PhD², Kenichiro Sugiyama, Phar.B.³, Wei Sun, Ph.D.¹, Yoshiumi Ouchi, M Eng⁴, Katsuyoshi Tsukii, MSC³, Gemma Clark, RGN RM⁴

¹Kyowa Kirin Pharmaceutical Development, Inc., USA, ²Osaka city university hospital, Osaka, Japan, ³Kyowa Hakko Kirin Co, Ltd, Japan, ⁴Kyowa Kirin International plc, UK

P80 - Cumulative aducanumab safety data from PRIME: a randomized, double-blind, placebo-controlled, Phase 1b study

Philipp von Rosenstiel MD¹, Tianle Chen, PhD¹, John O’Gorman, PhD¹, Min Yee, PharmD¹, Carmen Castrillo-Viguera, MD, PhD¹, Claudia Prada, MD¹, Christoph Hoch, MD¹, Roger M Nitsch, MD¹, Samantha Budd Haeberlein, PhD¹, Alfred Sandrock, MD, PhD¹

¹Biogen, Cambridge, MA, USA, ²Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland
P109 - The action for health in diabetes clinical trial: does a 10-year intensive multidomain lifestyle intervention provide cognitive benefits?
Kathleen M. Hayden, PhD1, José A. Luchsinger, MD2, Stephen R. Rapp, PhD1, Delilah R. Cook, CCRP1, Rebecca H. Neiberg, MS1, Judy L. Bahnsen, BA1, Tara D. Beckner1, Jerry M. Barnes, MA1, and Mark A. Espeland, PhD for the Look AHEAD MIND Study Group
Wake Forest School of Medicine, Winston-Salem, USA, 2Columbia University, New York, USA

P110 - Single and multiple dose safety, tolerability and pharmacokinetics of the selective M1 receptor partial agonist HTL0018318 in healthy volunteers
Tim Tasker MBBS1, Jan Liptrot PhD, Charlotte Baltiker PhD2, Ellen ‘t Hart PhD2, Erica Klaassen PhD2, Samantha Prins MD2, Thalia van der Doef PhD2, Mike Walker1, Giles A. Brown PhD1, Alastair Brown PhD1, Miles Congreve PhD1, Malcolm Weir PhD1, Fiona H. Marshall PhD1, David M. Cross PhD1, Geert Jan Groeneveld MD, PhD2, Pradeep J. Nathan PhD1, a
1Sosei Heptares, Cambridge UK, 2Centre for Human Drug Research (CDHR), Leiden, Netherlands, 3Department of Psychiatry, University of Cambridge, UK, 4Cross Pharma Consulting Limited, Cambridge, UK

P111 - Assessing the psychological and emotional impact of APOE and amyloid disclosure in the API Generation Program: interim findings
Jessica B. Langbaum, PhD1, Jason Karlawish, MD2, Scott Roberts, PhD1, Angela Bradbury, MD1, Scott Kim, MD, PhD1, Elisabeth McCarty Wood, MS1, Carolyn Langlois, MA1, Fonda Liu PharmD1, Marie-Emmanuelle PhD1, Marie-Laure Rouzade-Dominguez, PhD1, Angelitha Caputo, PhD1, Mauritz Bezuidenhoudt, M.Sc1, Cristina Lopez-Lopez, MD, PhD1, Ana Graf, MD1, Pierre N. Tariot, MD1, Eric M. Reiman, MD1
1Banner Alzheimer’s Institute, Phoenix, USA, 2University of Pennsylvania, Philadelphia, USA, 3University of Michigan, Ann Arbor, USA, 4National Institutes of Health, Bethesda, USA, 5Novartis Pharmaceuticals Corporation, East Hanover, USA, 6Novartis Pharma AG, Basel, Switzerland

P112 - Meta-analysis of two tau aggregation inhibitor Phase 3 trials in mild Alzheimer’s disease with low dose hydromethylthionine
Bjoern Schelter, PhD1,2, Claude Wischik, MD, PhD1,2
1Institute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK, 2TaulRx Therapeutics, Aberdeen, UK

Late Breaking Posters

LBP13 - Cognitive and mobility training as preventive measures in cognitively healthy patients and patients with MCI
Jessica B. Langbaum, PhD1, Jason Karlawish, MD2, Scott Roberts, PhD1, Angela Bradbury, MD1, Scott Kim, MD, PhD1, Elisabeth McCarty Wood, MS1, Carolyn Langlois, MA1, Fonda Liu PharmD1, Marie-Emmanuelle PhD1, Marie-Laure Rouzade-Dominguez, PhD1, Angelitha Caputo, PhD1, Mauritz Bezuidenhoudt, M.Sc1, Cristina Lopez-Lopez, MD, PhD1, Ana Graf, MD1, Pierre N. Tariot, MD1, Eric M. Reiman, MD1
1Banner Alzheimer’s Institute, Phoenix, USA, 2University of Pennsylvania, Philadelphia, USA, 3University of Michigan, Ann Arbor, USA, 4National Institutes of Health, Bethesda, USA, 5Novartis Pharmaceuticals Corporation, East Hanover, USA, 6Novartis Pharma AG, Basel, Switzerland

LBP14 - Evidence of Sustained Low Dose Bryostatin Efficacy for Treatment of Alzheimer’s Disease: Consistency of Multiple Evaluation Analyses
Daniel Alkon, PhD1, LJ Wei, PhD2, Richard Thompson, PhD3
1Neurotope,Inc, 2Harvard University, 3Johns Hopkins University

LBP15 - Enterovirus might be involved in Alzheimer’s disease - results from a phase Ila trial evaluating Apovir, an antiviral drug combination
Lars-Olof Wahlund, MD, PhD1, Lars Lindqvist MD, PhD2, Mikael Åström MSc, PhL3, Jacob Westman PhD4, Roger Bullock MD, PhD5, Suzanne Hendriksen6, Nina Lindblom, PhD7
1Karolinska University Hospital, Huddinge, Sweden, 2Karolinska University Hospital, Huddinge, Sweden, 3StatCons, Limhamn, Sweden, 4Apodemus AB, Söna, Sweden, 5Roger Bullock Consulting Ltd, S污ndan, UK, 6Pentara Corporation, Salt Lake City, USA

LBP16 - A randomized, placebo controlled, repeat dose phase 1 study of COR388 in older healthy volunteers and patients with Alzheimer’s disease
Samer Kaba, MD1, Casey Lynch1, Mark Ryder, DMD2, Ira Goodman, MD1, Steve Thien, MD1, Steve Dominy, MD1
1Cortexyme, S. San Francisco, CA, 2UCSF, San Francisco, CA, 3Bioclinica, Orlando, FL, 4Pacific Research Network, San Diego, CA

LBP17 - Souvenaid in cognitive deterioration. Our experience after 5 years of treatment and follow-up
Miquel Aguilar MD, PhD1 and Paquita Soler, Nurse1
1Àptima Mutua Terrassa, Catalunya, SPAIN
LBP18 - Is RAGE the missing link between diabetes and dementia? Results from a subgroup analysis of the STEADFAST trial
Carmen Valcarce, PhD1, Imogene Dunn, PhD1, Tom Soeder, MS2, and Aaron Burstein, PharmD2
1Vtv Therapeutics LLC, High Point, NC, USA, 2CATO Research Ltd, Durham, NC, USA

LBP19 - Aducanumab 48-month analyses from PRIME, a Phase Ib study in patients with early Alzheimer’s disease
Philipp von Rosenstiel, MD1, Samantha Budd Haeberlein, PhD1, Carmen Castrillo-Viguera, MD1, Tianle Chen, PhD1, John O’Gorman, PhD1, Raj Rajagovindan, PhD1, Dalshaben Patel, PhD2, Guanfang Wang, PhD2, Spyros Chalkias, MD1, LeAnne Storodos PharmD1, Claudia Prada, MD1, Christoph Hoch, MD1, Roger M Nitsch, MD1, Alfred Sandrock, MD, PhD1
1Biogen, Cambridge, MA, USA, 2Biogen, Maidenhead, UK, 3Cytel, Cambridge, MA, USA, 4Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

LBP20 - Lu AF20513, an active immunotherapy against amyloid beta, in development for patients in early stages of Alzheimer’s disease
Bjørn Sperling, MD1, Lars Østergaard Pedersen, PhD1, Neli Boneva, MD1, Dorthe Daugaard, MD1, Yudong Zhao, PhD1
1H. Lundbeck A/S, Valby, Denmark

LBP21 - Baseline Data from the API Autosomal Dominant Alzheimer’s Disease Colombia Trial
Pierre N. Tariot**, Francisco Lopera**, Kayce M. Sint1, Nan Hu2, Heather Guthrie1, Jillian Smith1, William Cho1, Jessica B. Langbaum1, Ronald G. Thomas1, Kewe Chen1, Yi Su1, Dhruman Goradia1, Pradeep Thyagur1, Paul S VanGilder1, Ji Luo1, Valentina Ghisays1, Wendy Lee1, Michael H. Malek-Ahmadi1, Hillary D. Protas1, Yinghua Chen1, Carole Ho1, Shehnaaz Suliman1, Sergio Alvarez2, Yafeel T. Quiroz2, Robert Paul1, Silvia Rios Romenets1, Eric M. Reiman**, and the API ADAD Colombia Trial Group
1Banner Alzheimer’s Institute, Phoenix, AZ, USA, 2Grupo de Neurociencias de Antioquia de Universidad de Antioquia, Medellin, CO, 3Genentech Inc., South San Francisco, CA, USA, 4Roche Products Ltd, Welwyn Garden City, UK, 5University of California, San Diego, CA, USA, 6Hospital Pablo Tobon Uribe, Medellin, CO, 7Harvard Medical School and Massachusetts General Hospital, Boston MA, USA
Theme 3. Clinical trials: Imaging

P10 - Diagnostic accuracy of [18F]FCI19S PET for identifying Alzheimer’s disease
Byung Hyeon Byun, MD, PhD1, Sang Moo Lim, MD, PhD1
1Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea

P35 - Annual atrophy rate in normal aging from a large single-center cohort in Korea
Yu Yong Choi1, Byung C. Kim2, Seong-Min Choi2, Kee Hyung Park1, Kyu Yeong Choi, Kun Ho Lee1
1National Research Center for Dementia, Chosun University, Gwangju, South Korea, 2Department of Neurology, Chosun University College of Medicine, Gwangju, South Korea

P62 - Impact of cerebral blood flow changes on 18F-flobetaben SUVR. A simulation study
Santiago Bullich, PhD1, Norman Koglin, PhD1, Susan De Santi, PhD1, Georg A. Becker, PhD1, Audrey Perrotin, PhD1, Aleksandar Jovalekic, PhD1, Andrew Stephens, MD, PhD1, Henryh Barthel, MD, PhD1, Osama Sabri, MD, PhD1
1Piramal Imaging GmbH, Berlin, Germany, 2Piramal Pharma Inc., Boston, MA, USA, 3Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany

P76 - F-AV-1451 in TDP-43 associated frontotemporal dementia
Ruben Smith, MD, PhD1; Alexander F Santillo, MD2; Maria Landqvist Waldó, MD, PhD2; Oskar Hansson, MD, PhD1
1Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden, 2Memory Clinic, Ängelholm Hospital, Ängelholm, Sweden

P113 - Predicting amyloid burden from cognitive assessment
Donald R. Royall, MD1,4, Raymond F. Palmer, PhD4 for the Alzheimer’s Disease Neuroimaging Initiative
1Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, 2Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA, 3South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P114 - The triple use of amyloid PET in Alzheimer’s disease
Federica Ribaldi, MS1,2, Moira Marizzoni, PhD1, Valentina Garibotto, MD1, Michela Pievani, PhD1, Giovanni B Frisoni, MD1,3
1IRCCS Fatebenefratelli, Brescia, Italy, 2University of Brescia, Brescia, Italy, 3Geneva University Hospitals, Geneva, Switzerland

P115 - A comparison of cortical reporter regions for longitudinal analysis of 18F-AV1451 PET data
David Scott, PhD1, Kataryzna Adamczuk, PhD1, Beth Gorman, BS CNMT2, Maureen Runtle, BS CNMT R.T. (N.)2, Joyce Suhy, PhD1 and the Alzheimer’s Disease Neuroimaging Initiative
1Bioclinica, Newark, CA, USA, 2Bioclinica, Philadelphia, PA, USA

P116 - Can tau PET imaging be instrumental in predicting an elevated amyloid level in clinical trials?
Sergey Shcherbinin, PhD1, Michael J. Pontecorvo, PhD1, Ming Lu, MD, MS, MPH2, Michael D. Devous Sr, PhD1, A. Joshi, PhD1, Sudeepti Southetakal, PhD1,2, Emily C. Collins, PhD1,2, Adam S. Fleisher, MD1, Mark A. Mintun, MD1,3
1Eli Lilly & Co, Indianapolis, IN, USA, 2Bioclinica, Philadelphia, PA, USA

P117 - Supratentorial white matter is a better reference for longitudinal quantification of [18F]Flutemetamol scans
Gemma Salvador MSc1, Chris Foley PhD2, Elisabetta Grecchi, PhD31, M. Jorge Cardoso, PhD2,3, Isadora Lopes-Alves, PhD2, Pawel Markiewicz, PhD2, Caires Falcon, PhD1, Marks Battle MSc2, Adriaan A. Lammertsma, PhD1, Mark Schmidt, MD, PhD1, José Luis Molinuemo MD PhD2, Frederik Barlbhof, MD, PhD2,4, Juan Domingo Gispert, PhD1
1BarcelonaBeta Brain Research Center, Barcelona, Spain, 2GE Healthcare, Amersham, United Kingdom, 3XICO, London, United Kingdom, 4King’s College London, London, United Kingdom, 5University College London, London, United Kingdom, 6VU Medical Center, Amsterdam, The Netherlands, 7Janssen Pharmaceutica, Beerse, Belgium

P118 - Clinical validation of 18F-PI-2620 for quantification of tau in subjects with Alzheimer’s disease
Andrew Stephens1, Andre Mueller1, Santiago Bullich1, Mathias Berndt1, John Seibyl1, Olivier Barrier2, Jennifer Madonia2, Helko Kroth1, Andrea Pfeifer1, Andreas Muhs1, Gilles Tamagnan1, Kenneth Marek1, Ludger Dintelborg1
1Piramal Imaging, Berlin, Germany, 2Inivica, New Haven, USA, 3AC Immune SA, Lausanne, Switzerland

P119 - Cut-off for 18F-flutemetamol SUVR with white matter reference region
Katarzyna Adamczuk, PhD1, David Scott, PhD1, Ben Newton, PhD1, Joyce Suhy, PhD1, Michael Egan, MD2, Symon Wee3, Roger Gunn2, Ajay Verma1
1Bioclinica, Newark, CA, USA, 2Merck Sharp & Dohme, Kenilworth, NJ, USA, 3General Electric Health Care, Amersham, UK

P120 - Amyloid PET Imaging in a Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study with UB-311
Hui Jing Yu1, Hui-Chen Chen1, Jacob Hesterman2, Jack Heimann2, Sean Holmes2, Alex Whittington2, Xue Wang2, Roger Gunn2, Ajay Verma1
1United Neuroscience, Inc. Hauppauge, NY, USA, 2Inivica, A Konica Minolta Company, Boston, MA, USA
P121 - Cortical dopamine depletion and cognition in Lewy bodies disorders: a 123I-FP-CIT single-subject study
Andrea Pilotto2, Francesca Schiano di Cola1, MD and MD, Enrico Premi1, MD, Roberto Grassol PsyD, Rosanna Turroni, PsyD, MD; Stefano Gipponi1, MD, Andrea Scalvini1, MD; Elisabetta Cottini1, Barbara Paghera1, Laura Bonanni1, PhD, MD; Maria Cristina Rizzetti1, PhD; Barbara Borroni1, MD; Alessandro Padovani1, PhD, MD
1Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. 2Parkinson’s Disease Rehabilitation Centre, FERB ONLUS S.Isidoro Hospital, Trescore Balneario (BG), Italy. 3Nuclear Medicine Unit, University of Brescia, Brescia, Italy. 4Department of Neuroscience Imaging and Clinical Sciences, University G. d’Annunzio of Chieti-Pescara, Chieti, Italy

P122 - Very early detection and treatment monitoring of Alzheimer’s Disease in the retina by multimode, hyperspectral confocal scanning ophtalmoscopy
Daniel L. Farkas1,2, Fartash Vasefi, PhD1, Jeanne M. Fontana, MD, PhD1
1The Brain Window, Inc., Sherman Oaks CA, USA. 2University of Southern California, Los Angeles CA, USA

P123 - Quantitative Analysis on The Goodness of Harmonization with Multivariate Analysis of Field Strength, Sex, Age and Total Intracranial Volume
Mirza Faisal Beg, PhD1, Da Ma, PhD, Karteek Popoli, MD, MA, U Wang, PhD1
1School of Engineering Science, Simon Fraser University, Vancouver, BC, Canada. 2Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. 3Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

P124 - Prescribing Cholinesterase inhibitors in mild cognitive impairment – observations from the Alzheimer’s Disease Neuroimaging Initiative
Eddie Stage1, Diana Svaldi PhD1, Sophie Sokolow PhD MPharm2,3,4, Shannon L. Risacher PhD1, Krisztina Marosi1, Kwangsik Nho PhD1, Jerome I Rotter MD1,4, Andrew J. Saykin PsyD1, Liana G. Apostolova MD MS1
1Indiana Alzheimer Disease Center, Indianapolis, IN, USA. 2UCLA School of Nursing, Los Angeles, CA, USA. 3Division of Genomic Outcomes, Department of Pediatrics and Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA. 4Institute for Translational Genomics and Population Sciences and Department of Pediatrics, Los Angeles Biomedical Research Institute, Torrance, CA, USA. 5UCLA Brain Research Institute, Los Angeles, CA, USA. 6UCLA Clinical and Translational Science Institute, Los Angeles, CA, USA

Late Breaking Posters

LBP21 - Prediction of Treatment Response to Donepezil using Automated Hippocampal Subfields Volumes Segmentation in Patients with Mild Alzheimer’s Disease
Sheng-Min Wang, MD, PhD1, Yoo Hyun Um, MD, PhD1, Chang-Ult Lee MD, PhD1, and Hyun Kook Lim, MD, PhD1
1Department of Psychiatry, Yonsei UI, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 2St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of Korea. 3Department of Psychiatry, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

LBP22 - Role of Confluent White Matter Lesions in the progression to Alzheimer’s dementia in an Asian Clinic Cohort
Nagaendran Kandiah
National Neuroscience Institute, Singapore

LBP23 - APOE4/4 Early to Mild AD Subjects Show High Rates of Hippocampal Atrophy and Cognitive Decline in ADNI-1 and Trimprostate Datasets
Susan Abushakra MD1, Luc Bracoud MS2, Joel Schaerer3, Aidan Power MD1, John Hey PhD1, David Scott PhD1, Joyce Suhy PhD1, Martin Tolar MD PhD2 & the Alzheimer Disease Neuroimaging Initiative (ADNI)
1Alzheon Inc., Framingham, MA, USA, 2Bioclinica, Lyon France, 3Bioclinica, Newark CA, USA

LBP24 - Preliminary characterization of 18F-RO948 PET imaging among cognitively unimpaired and patients with MCI or dementia in the BioFINDER2 study
Gregory Klein1, Ruben Smith2, Sebastian Palmedo3, Niklas Mattsson2, Daniëlle van Westen2, Olof Strandberg3, Jonas Jögi2, Tomas Ohlsson2, Edilio Borroni1, Preciosa Coloma1, Erik Stomrud1, Oskar Hansson2
1Roche Pharma Research and Early Development, Basel, Switzerland. 2Clinical Memory Research Unit, Lund University, Sweden
Theme 4. Clinical trials: Biomarkers including plasma

P1 - Sustained attention and memory tasks with concurrent EEG provide potential biomarkers for mild cognitive impairment
Shani Waninger, Ph.D.¹, Chris Berkal, Amir Meghdadi, Ph.D.², David Salat, M.D.² and Ajay Verma, M.D., Ph.D.³
¹Advanced Brain Monitoring, Inc., Carlsbad, CA, ²MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, ³United Neuroscience, Dublin, Ireland

P4 - High correlation in the Aβ40 and Aβ42 levels in human cerebrospinal fluid as measured by ELISA and HPLC-MS/MS
José A. Allué, PhD, Leticia Sarasa, PhD, Virginia Pérez-Grijalba, PhD, Noelia Fandos, PhD, Pedro Pesini, PhD, Manuel Sarasa, PhD.
Araclon Biotech S.L., Vía Hispanidad 21, 50.009, Zaragoza, Spain

P22 - Cerebrospinal fluid biomarkers in J-ADNI: diagnostic accuracy in AD and predictability of future clinical change in MCI
Kazumi Suzuki, MD, PhD, ¹ Ryoyo Ihara, MD, PhD, ¹ Atsushi IWata, MD, PhD, ¹ Tateshi Iwatsubo, MD, PhD, ¹ Kenji Ishii, MD, ¹ Tateshi Itouchi, MD, PhD, ¹ Ryozo Kikuno, MD, PhD, ¹ Japanese Alzheimer’s Disease Neuroimaging Initiative
¹The University of Tokyo, Tokyo, Japan, ²Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, ³Niigata University, Niigata, Japan

P28 - Analytical performance of the Lumipulse® G pTau 181 and Lumipulse® G β-Amyloid 1-40 assays
Manu Vandijck, Martine Dauwe, Rosina Degireich, Els Huyck, Nathalie Le Bastard, Geert Jannes, Vesna Kostanjevček
Fujirebio Europe N.V., Ghent, Belgium

P30 - Curcumin is Detectable in Human Cerebrospinal Fluid after Oral Administration of Turmeric Extract HSRx-888
Norman Relkin MD, PhD, ¹ Dan Li PhD, ¹ Joshua Costin PhD, ¹ David Wyatt MD²
¹Relthirn Consulting LLC, Harrington Park, NJ 07640, ²HerbalScience Group, Naples FL, USA, ³Syneos Health, Miami FL, USA

P39 - Diagnostic biomarkers’ clinical applicability in early onset Alzheimer’s disease
Neus Falgas, Raquel Sánchez-Vallé, Mircea Balasa, Sergi Borrego, Magdalena Castelví, Adrià Tort-Merino, Jaume Olives, Beatriz Bosch, Guadalupe Fernández, Francisco Lomeña, Nuria Bargalló, Albert Liado
¹Alzheimer’s disease and other cognitive disorders Unit. IDIBAPS, Hospital Clinic de Barcelona, ²Atlantic Fellow for Equity in Brain Health. Global Brain Health Institute. Trinity College Dublin, Ireland, ³Nuclear Medicine Department. IDIBAPS. Hospital Clinic de Barcelona, 4Image Diagnostic Centre. IDIBAPS. Hospital Clinic de Barcelona

P46 - Inverse association between Aβ42/40 plasma ratios and fibrillary amyloid deposition in the brain: results of the FACEHBI study
Iziar de Rojas, MSc, Judith Romero, MSc, Octavio Rodriguez-Gomez, MD, Pedro Pesini, PhD, Angela Sanabria, PhD, Alba Pérez-Cordon, MSc, Carla Abdellou, MSc, Isabel Hernández, MD, PhD, Maitee Rosende-Roca, MD, Maite Rosende-Roca, MD, Ana Espinosa, PhD, Gemma Ortega, PhD, Silvia Gil, MD, PhD, Marina Guirtat, MSc, Anna Gallahajeta, MSc, Miguel Angel Santos-Santos, MD, PhD, Sonia Moreno-Grau, MSc, Oscar Sotolongo-Grau, PhD, Susana Ruiz, MN, Laura Montreuil, MLL, Elvira Martin, MSc, Estef Peleja, Francisco Lomeña, MD, PhD, Francisca Campos, PhD, Assumpta Vivas, MD, Marta Gómez-Chiari, MD, Miguel Angel Tejero, MSc, Joan Giménez, M.D., Virginia Pérez-Grijalba, PhD, Marta Marquié, MD, PhD, Gemma Monté-Rubio, PhD, Sergi Valero, PhD, Adelina Orellana, PhD, Lluis Tarraga, MSc, Manuel Sarasa, PhD, Agustin Ruiz, MD, PhD, Mercè Boada, MD, PhD, on behalf of the FACEHBI study
¹Research Center and Memory Clinic. Fundación ACE. Institut Català de Neurociències Aplicades, UIC-Barcelona, Spain, ²Servei de Medicina Nuclear, Hospital Clínic i Provincial. Barcelona, Spain, ³Departament de Diagnòstic per la Imatge. Clínica Corachan, Barcelona, Spain

P57 - Concordance of the CSF Abeta42/Abeta40 ratio with amyloid-PET in the BioFINDER study
Oskar Hansson MD, PhD, ¹ Katharina Zinth MSc, ² Simone Wahl PhD, ¹ Monika Widmann ChTech², Sandra Rutz PhD², Maryline Simon PhD², Kai Blennow MD PhD²,³
¹Advanced Brain Monitoring, Inc., Carlsbad, CA, ²MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, ³United Neuroscience, Dublin, Ireland

P64 - Novel pre-analytical protocol for handling of cerebrospinal fluid samples for the analysis of Alzheimer’s Disease biomarkers in clinical practice
Oskar Hansson MD, PhD, ¹ Erik Stromrud MD PhD²,³ Sandra Rutz PhD²,³ Valeria Lifte PhD³, Ekaterina Bauer MBA PhD³, Udo Eichenlaub PhD³, Richard Batrla MD PhD,³ Ehaterina Manuillova MSc³, Mehmet Can Mert PhD³, Simone Wahl PhD³, Kai Blennow, MD, PhD. ³
¹Clinical Memory Research Unit, Lund University, Malmö, Sweden, ²Memory Clinic, Sthöne University Hospital, Malmo, Sweden, ³Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany, ⁴Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany, ⁵Centralised & Point of Care Solutions, Roche Diagnostics International, Rotkreuz, Switzerland, ⁶Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden, ⁷Institute of Neuroscience and Physiology, Dept. of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Malmöld, Sweden.
P65 - Serum-Based Proteins as Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Shu Yu1, Yue-Ping Liu2
1State Key Laboratory of Military Stomatlogy and National Clinical Research Center for Oral Disease and Shaanxi Clinical Research Center for Oral Disease, Department of Laboratory Medicine, School of Stomatlogy, Fourth Military Medical University, Xi’An, Shaanxi Province 710000, China, 2Department of Laboratory Medicine, 477th Hospital of PLA, Xiangyang, Hubei Province 400013, China. * Corresponding author

P66 - TREM2 DNA methylation: A potential biomarker or therapeutic target
Lynn Bektris1, Rumana Akhter1, Yvonne Sha0, Maria Khrestian1, Giana D’Ale0, Shane Formica1, James B. Leverenz2
1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, 2Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio

P73 - Immune state in cognitive impairment of aged and the use of Actovegin and Ceraxone in out-patients of Alzheimer’s centre
Nataliya Milhavlov1, Lubov Androsova2
1MD, PhD, Ceramic psychiatry Department, Mental health research centre, Moscow, Russia, 2PhD, Immunology laboratory, Mental health research centre, Moscow, Russia

P78 - Modifiable Alzheimer’s risk biomarkers
Christine Ganzer1, Alon Seifan, MD2, Krista Ryon1, Elizabeth Maiche MCMSc, PA-C4
1Hunter College, NY, 2NeuralWell Free, Ft. Lauderdale, Florida, 3Hunter College, NY, 4NeuralWell Free, Ft. Lauderdale, Florida

P81 - Serum NFL, TAU, GFAP and UCH-L1 in Alzheimer disease patients with different decline profile
Mélanie Jacob, MD2,3, Alecsandra Maceshi, PhD2, Siene Richarda PhD1, Audrey Gabelle MD, MD1,2,4, Sylvain Lehmann MD, PhD2,3
1Memory Research and Resources Center, Department of Neurology, Montpellier University Hospital, Montpellier, France, 2Université de Montpellier, MUSE, Montpellier, France, 3Inserm U1183 IRMB, Montpellier, France, 4Inserm U1061, La Colombière Montpellier University Hospital, Montpellier, France

P125 - An ultra-sensitive molecular immuno-assay for quantification of human SNAP25 in cerebrospinal fluid
Eugene Vannmechein, PhD1, Jeroen Vanbrabant, PhD2, Naome De Rooyc, BcSc2, Maria Bjertte, PhD2, Sebastiana Engelborghs, MD, PhD2,3, Ann De Vosc, PhD1
1ADx NeuroSciences NV, Ghent, Belgium, 2Reference Center for Biological Markers of Dementia (BIODERM), University Born-Bunge, University of Antwerp, Antwerp, Belgium, 3Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium

P126 - Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down Syndrome. A cross-sectional study
Maria Carmona-Iragui1, MD, PhD2,3, Bessy Benejam, MSc4, Susana Fernandez, MD2, Laura Videla, MSc2,3, Isabel Barroeta, MD, PhD1,3, Daniel Alcolea, MD, PhD2,3, Jordi Pegueroles, MSc2,3, Laia Muñoz, MSc2,3, Olivia Belbin, PhD2,3, Jordi Clarimón, PhD1,3, Mony John de Leon, EoD4, Sebastián Videla, MD, PhD1,3, Alecsandra Maleska Maceshi, MSc2,3, Christoph Hirtz, PhD2,3, Constance Delaby, PhD2,3, Sylvain Lehmann, PhD2,3, Rafael Blesa, MD PhD1,2, Alberto Llo2, MD, PhD1, Juan Forde, MD PhD2,3
1Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau- Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain, 2Barcelona Down Medical Center: Fundació Catalana de Sindrome de Down, Barcelona, Spain, 3Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain, 4New York University School of Medicine, NYU Center for Brain Health, Department of Psychiatry, New York, USA, 5Clinical Research Support Unit, Bellvitge University Hospital / Bellvitge Biomedical Research Institute (IDIBELL) / University of Barcelona, Barcelona, Spain, 6Université de Montpellier, CHU de Montpellier, Montpellier, France

P127 - The application of Polygenic Risk Score analysis to Stratification of Subjects for Clinical Trials in Alzheimer’s Disease in carriers and non-carriers of the ApoE4 risk allele
Richard Pither1, PhD1, Ganna Leonenko1, Rebecca Simms1, Paula Daunt PhD2, Greg Davidson PhD2, Alex Gibson PhD2, Olusungun Oshota PhD2, Maryam Shoai PhD2, Kevin Banst3, Simon M Law3, PhD2, Zsuzsanna Nagy1 and John Hardy, PhD2, DSc2, Julie Williams PhD2,3, Valentina Escott-Price2, PhD2
1Cardiff University, United Kingdom, 2Cytox Ltd, UK, 3Oxford, United Kingdom, 3UCL Institute of Neurology, London, United Kingdom, 4Edith Cowan University, and Cooperative Research Centre (CRC) for Mental Health, Perth, Australia, 5University of Birmingham, United Kingdom, 6Dementia Research Institute, Cardiff, United Kingdom

P128 - Do short Aß-peptides impact the time course of cognitive decline? An ADNI analysis
Markus von Ikken1, PhD, Paul Delmar, PhD, Katharina Buck, PhD2, Charlotta Schärfe2, Simone Wahl, PhD2, Karlheinz Baumann, PhD2, Irene Gerlach, PhD1, Tania Nikholcheva, MD, PhD1
1pRED NORD, Roche Innovation Center Basel-Switzerland, 2Biostars and Data Management, Roche Innovation Center Munich - Germany

P129 - Measuring oligomerization tendency of plasma as a new blood-based biomarker for Alzheimer’s disease
SangYun Kim, MD, PhD1,2, Sungmin Kang, MS1,2, Seong Soo A. An, PhD2, Young Chul Youn, MD, PhD2
1Department of Neurology, Seoul National University College of Medicine; 2Clinical Neuroscience Center, Seoul National University Bundang Hospital, 3PeopleBio Company, 4Department of Bionano Technology, Gachon Medical Research Institute, Gachon University, 5Department of Neurology, Chung-Ang University College of Medicine
CTAD 2018

POSTERS PRESENTATION

PI30 - Transcranial magnetic stimulation predicts cognitive decline in Alzheimer’s disease patients
Giacomo Koch, MD, PhD1,2, Caterina Motta MD1, Francesco Di Lorenzo MD1, Maria Concetta Pelliciari PhD1, Maria Bonni PhD2, Silvia Picazio PhD1, Carla Caltagirone MD2, Alessandro Martorana MD1
1Department of Behavioural and Clinical Neurology, 2Santa Lucia Foundation IRCCS, Rome, Italy, 3University of Tor Vergata, Rome, Italy

PI31 - Non-core biomarkers (neurofilament light, neurogranin, I4-3-3 and YKL-40) in the Alzheimer’s disease continuum, frontotemporal dementia and prion diseases diagnosis
Anna Antonell, PhD1, Adrià Tort, MSc1, José Rios, MSc2, Sergi Borrego, MD1, Mircea Balasa, MD1, Cristina Muñoz-García1, Beatriz Bosch, PhD2, Neus Falgàs, MD1, Lorena Rami, PhD1, Kaj Blennow, MD, PhD1, Henrik Zetterberg, PhD4,5, José Luis Molinuevo, MD, PhD1, Albert Lladó, MD, PhD1, Raquel Sánchez-Valle, MD, PhD2
1Alzheimer’s disease and other cognitive disorders Unit, Hospital Clinic. IDIBAPS, Barcelona, Spain, 2Medical Statistics Core Facility, Institut d’ Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Hospital Clinic. Barcelona. Bioinformatics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, 3Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrensa Academy, at the University Center of Gothenburg, Mölndal, Sweden, 4Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, 5Department of Molecular Neuroscience, University College London, London, UK

PI32 - Amyloid blood biomarker detect Alzheimer’s disease
Klaus Cerwen, Prof. Dr.
1Ruhr-Universität Bochum, Bochum, Germany

PI33 - Early diagnosis of Mild Cognitive Impairment and Alzheimer’s disease based on salivary lactoferrin
Eva Carrillo1, Gorha Oribe2
1Networked Biomedical Research Center in Neurodegenerative Diseases (CIBERNED), Spain; 2Group of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (inmas12), Madrid, Spain

PI34 - Exome-sequencing in patients with early-onset Alzheimer’s disease and Frontotemporal dementia: causal mutations and genetic variants in risk genes for dementia
Anna Antonell, PhD1, Raquel Sánchez-Valle, MD, PhD, Neus Falgàs, MD1, Mircea Balasa, MD, PhD1, Debayan Datta, PhD2, Lluis Armengol, PhD2, Sergi Borrego, MD1, Guadalupe Fernández1, Beatriz Bosch, PhD1, Jaume Olives1, Cristina Muñoz-García1, Maria León1, Magdalena Castellvi1, Adrià Tort1, Albert Lladó, MD, PhD1
1Alzheimer’s disease and other cognitive disorders Unit, Hospital Clinic. IDIBAPS, Barcelona, Spain, 2Medical Statistics Core Facility, Institut d’ Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Hospital Clinic. Barcelona. Bioinformatics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, 3Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrensa Academy, at the University Center of Gothenburg, Mölndal, Sweden, 4Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, 5Department of Molecular Neuroscience, University College London, London, UK

PI35 - The future of blood-based hinase biomarkers in Alzheimer’s disease
Jacques Hugon, Julien Dumurgier, Emmanuel Cognat, Claire Paquet
Center of Cognitive Neurology, Lariboisière Hospital, AP-Hôp, University of Paris Diderot, Paris France

PI36 - A prototype SIMOA assay quantifying plasma amyloid beta 1-42 and 1-40 isoforms can differentiate AD from healthy control subjects
Charlotte E. Teunissen, PhD1, Elisabeth Thijssen, MSc2, Inge M. W. Verberkt, MSc2, Hugo Marcel Vanderstichele, PhD1, Hans Heijstj, Harry Twaalthoven1, Kimberly Mauroo BSc1, Philip Scheltens, MD, PhD1, and Erith Stoops, Eng2
1Neurochemistry Laboratory and Biobank, Amsterdam University Medical Center, Amsterdam, Netherlands, 2Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Neuroscience, Amsterdam University Medical Center Amsterdam, Netherlands, 3ADx NeuroSciences, Genit, Belgium, 4Amsterdam University Medical Center, Department of Neurology, Amsterdam, Netherlands

PI37 - Serum-Based Proteins as Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Shu Yu1, Yue-Ping Lii2
1State Key Laboratory of Military Stomatology and National Clinical Research Center for Oral Disease and Shaanxi Clinical Research Center for Oral Disease, Department of Laboratory Medicine, School of Stomatology, Fourth Military Medical University, Xian, Shaanxi Province China, 2Department of Laboratory Medicine, PLA, Xiangyang, Hubei Province, China. * Corresponding author

PI38 - Inflammatory markers tracking cognitive and biomarker heterogeneity in MCI stage of Alzheimer’s Disease
Jagan A Pillai1, MBBS PhD2,3, James Bena MS1, Lynn M Bekris PhD2, James B Leverenz MD2,3
1Lou Ruvo Center for Brain Health, *Neurological Institute and 2Department of Neurology, *Quantitative Health Sciences, 2Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH USA

PI39 - The pitfalls for clinical trials of the use of time points earlier than 90 min for the [18F]MK-6240 SUVr calculation
Tharich A. Pascoal MD1, Sulantha Mathotaarachchi MSc1, Mira Chamoun PhD2, Joseph Therriault BSc1, Robert Hopewell PhD2, Cassan Massarweh PhD1, Andrea L. Benedet1, MSc, BSc, Min Su Kang1, Serge Gauthier, MD, Pedro Rosa-Neto1, MD, PhD
1Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada
Late Breaking Posters

**LBP25 - Discovery of an Endogenous Metabolite of Tramiprosate and its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in Human Brain**

John A. Hey,1 Petri Kocis, Jakub Hort,2,3 Susan Abushahral, Aidan Power,1 Martin Vyhánek2,3, Jeremy Y. Yu1 and Martin Tolar1

1Alzheon, Inc, Framingham, MA, USA, 2International Clinical Research Centre, St. Anne’s University Hospital Brno, Brno, Czech Republic, 3Cognitive Center, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic

**LBP26 - Novel use of aptamer libraries for prediction of amyloid status from blood serum**

Gregory Penner1, Sezic Lecocq, Anaëlle Chopin, Simone Lista2,3, Andrea Vergallo3,4, Enrica Cavedo3,4,5, Francois-Xavier Lejeune6 and Harald Hampel2,3,7,8,9 the INSIGHT-preAD study group and the Alzheimer Precision Medicine Initiative (APMI)

1NeuroNeuro SAS, Villejuif, Bio Park, Villejuif, France, 2AXA Research Fund & Sorbonne University Chair, Paris, France, 3Sorbonne University, CRC n° 2L, Alzheimer Precision Medicine (APM), AP-HS, Pitié-Salpêtrière Paris, France, 4Brain & Spine Institute (ICM), INSERM U127, CNRS UMR 7225, Paris, France, 5Institute of Memory and Alzheimer’s Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HS, Paris, France

**LBP27 - Novel cerebrospinal fluid synaptic markers in Alzheimer’s disease for potential use in clinical trials**

Alberto Lleo1, MD, PhD1, Raúl Núñez-Llaves2,3, Daniel Alcolea MD, PhD2, Martí Colom-Cadena PhD2,3, Laia Muñoz2,3, Marta Querol-Vilaseca2,3, Jordi Pegueroles1,2, Lorena Rami PhD1, Albert Lladó MD, PhD1, José L. Molinuevo MD, PhD1, Mikel Tainta MD, PhD1, Jordi Clarimón PhD1,3, Taro Spires-Jones PhD3, Ana Gámez-Valero, PhD3,4, Andrea Vergallo2,3,4,5, Enrica Cavedo2,3,4,5, Ana Hervás, MD3,4,5, Ramón Reñé MD, PhD1,2, Daniel Alcolea PhD1,2, Martí Colom-Cadena PhD1,2, Raquel Sánchez-Valle MD, PhD1,2, Alex Bayes MD2,3, Olivia Belbin PhD2,3

1Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIERNEBD), Madrid, Spain, 3Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain, 4Alzheimer’s Disease and Other Cognition Disorders Unit, Neurology Department, Hospital Clinic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 5Department of Neurology, Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain, 6Centre for Discovery Brain Sciences and UK Dementia Research Institute, University of Edinburgh, 7Molecular Physiology of the Synapse Laboratory, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain, 8Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallés), Spain

**LBP28 - Diminished platelet-derived hsa-mir-150-5p expression as biomarker for dementia with Lewy bodies versus Alzheimer’s disease**

Katrin Beyer1, PhD1, Ana Gámez-Valero, PhD2, Jaume Campdelacreu, MD, PhD1, Dolores Vilas, MD, PhD1, Lourdes Ispierto, MD, PhD1, Jordi Gascón-Bayarri, MD1, Ramón René, MD, PhD1, Ramiro Álvarez, MD1, Maria P Armengol, PhD1, Francesc E. Borra, PhD2

1Department of Pathology, Health Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain, 2REMAR-IVECAT group, Health Sciences Research Institute Germans Trias i Pujol, Badalona, Spain, 3Department of Neurology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, 4Department of Neurology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 5Genomic and Microscopy facilities, Institut Investigació Ciències de la Salut Germans Trias i Pujol (ICGP), Badalona (Barcelona), Spain

**LBP29 - Development of polygenic risk scores (PRS) for common neurogenophathy**

Julie Collens1, PhD1, Milte Nalis, PhD1, Marcel van der Brug, PhD1

1Vivid Genomics, Inc, San Diego, CA, USA

**LBP30 - The Italian Inter-Societal consensus for the biomarker-based diagnosis of mild cognitive impairment**

Marina Boccardi, PhD1, Cristina Nicolosi, MD2, Cristina Festari, MS2,1, Angelo Bianchetti, MD1,6, Stefano Cappa, MD1,7, Davide Chiasseri, PhD1,2, Andrea Falini, MD1,2,3, Ugo Paolo Guerra, MD1,4, Flavio Nobili, MD1,4,5, Alessandro Padovani, MD1,4,5, Giulia Maria Sancesario, PhD1,2, Francesca Benedetta Pizzini, PhD1,2,1, Alberto Beltramello, MD1,4,5, Marcello Ciaccio, MD1,4,5, Orazio Schillaci, MD1,4,5, Marco Trabucchi, MD1,4,5, Fabrizio Tagliavini, MD1,2, Giovanni Battista Frisoni, MD1,4,5

1Laboratory of Neuroimaging and Alzheimer’s Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, 2LANVIE, Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland, 3University of Brescia, Department of Molecules and Translational Medicine, Brescia, Italy, 4Medicine and Rehabilitation Department, Istituto Clinico S. Anna, Brescia, Italy, 5Italian Psychogenetic Association (AIP), Brescia, Italy, 6NECS Center, Scuola Universitaria Superiore IUSS, Pavia, Italy, 7Italian Society of Neurology, Association for the Study of the Dementias (SINdem), Rome, Italy, 8Section of Neurology, Department of Medicine, University of Perugia, Perugia, Italy, 9Italian Society of Clinical Biochemistry and Clinical Molecular Biology, Laboratory Medicine (SIBioC), Italy, 10Division of Neuroscience, IRCCS San Raffaele, Milan, Italy, 11Vita-Salute San Raffaele University, Milan, Italy, 12Neurorehabilitation Unit, IRCCS San Raffaele hospital, Milan, Italy, 13Italian Association of Neurorehabilitation (AINR), Italy, 14Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy, 15Italian Association of Nuclear Medicine (AINM), Italy, 16Clinical Neurology, Dept of Neuroscience (DNOGM), University of Genova, Italy, 17IRCCS Ospedale Policlinico San Matteo, Genova, Italy, 18Neurology Clinical Department of Clinical and Experimental Sciences, Brescia, Italy, 19Department of Clinical and Behavioural Neurology, Santa Lucia Foundation, Rome, Italy, 20Department of Neuroradiology, General Hospital, Verona, Italy, 21Department of Diagnostic and Specialized Medicine, IRCCS Ospedale Policlinico San Matteo, Genova, Italy, 22Department of Biopathology and Medical Biotechnologies, University of Palermo, Palermo, Italy, 23Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy, 24Tor Vergata, Rome University, Rome, Italy, 25Division of Neurology V/Neuropathology, Fondazione IRCCS Istituto Neurologico “C. Besta”, Milan, Italy, 26Memory Clinic, University Hospital, Geneva, Switzerland

**LBP31 - Secondary structure of Aβ as blood biomarker**

Klaus Gerwert Department of Biophysics Ruhr University Bochum, Germany
LBP32 - BDNF as a biomarker for the effects of p38 MAPKα inhibition on IL-1β-induced impairment of hippocampal synaptic plasticity
John Alam MD1, Charlotte Teunissen PhD2, Niels Prins MD PhD3,4, Hui-May Chu PhD2, Philip Scheltens MD PhD1
1EIP Pharma Inc, Cambridge MA, USA, 2Department of Clinical Chemistry, VU University Medical Center, Amsterdam, NL, 3Department of Neurology and Alzheimer Centre, VU University Medical Center, Amsterdam, NL, 4Brain Research Center, Amsterdam, NL, 5Anoixis Corporation, Framingham MA, USA

LBP33 - Impact of pre-analytical sample handling on Elecsys Aβ40, Aβ42 and tTau immunoassays in plasma
Malgorzata Rozga, PhD1, Tobias Bitner, PhD2, Richard Batrila-Utermann, MD, MBA1, Johann Karl, PhD1
1Roche Diagnostics GmbH, Penzberg, Germany, 2Genentech, A member of the Roche Group, Basel, Switzerland, 3Roche Diagnostics International AG, Roche, Switzerland

LBP34 - Agreement between visual amyloid PET and cerebrospinal fluid Aβ1-42, Aβ1-40, t-Tau and p-Tau on the LUMIPULSE G fully automated platform
Alberto Lleó1,2, Jordi Pegueroles2, Laia Muñoz2, Valle Camacho2, Diego López-Mora3, Alejandro Fernández-León3, Nathalie Le Bastard3, Elis Huycht4, Alicia Nadal4, Verónica Olmedo4, Víctor Montal1,2, Eduard Viaplana1, Rafael Blesa1, Juan Fortea3, Daniel Alcolea3
1Sant Pau Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, 2Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain, 3Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, 4Fujirebio Europe NV, Gent, Belgium, 5Fujirebio Iberia, SLU, Barcelona, Spain

LBP35 - Does non-disclosure of APOE genotyping prevent subject interest or participation in clinical trials?
Sean Stanton1, Vishnuharkit Nitta, MS2, Jessica Branning, BS2
1LifeCore Solutions, Winter Park, USA, 2ClinCloud, LLC, Orlando, USA

LBP36 - Measurement of pathological amyloid in a patient cohort in routine clinical assessment: comparison of visual [18F]Flutemetamol PET read and CSFs measures
Nenad Boodanovic1, Enrico Fantoni1 & Gill Farrar2
1Karolinska Institutet, Stockholm, Sweden and University Hospital Oslo, Oslo University, Norway, 2GE Healthcare Life Sciences, Amersham, UK and Boston, USA

LBP37 - Kinetic measurement of newly generated BACE1-cleaved APP in the human central nervous system in Alzheimer’s disease: a pilot study
Robert J. Vassar, PhD1, Randall J. Bateman, MD2, Bruce W. Patterson, PhD3, Justyna A. Dobrowolska Zaharia, PhD1
1Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA, 2Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA, 3Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA

LBP38 - Reliability of a rapid APOE assay for Alzheimer’s risk assessment and clinical trial screening
Athene Lee, PhD1,2, William Menard, BA1, Gina Tonini, MBA1, Louisa Thompson, PhD1 2Jessica Alber, PhD1 2Stephen Salloway, MD1 2
1Warren Alpert Medical School of Brown University, Providence, RI, USA, 2Butler Hospital, Providence, RI, USA

LBP39 - Cerebrospinal fluid profiling of multiple pathophysiological pathways in Alzheimer’s disease
Steven Arnold MD, PhD1, Bianca A. Trombetta4, Becky C. Carlyle, PhD2
1Massachusetts General Hospital and Harvard Medical School, 2Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

LBP40 - Interim biomarker analyses of phase II study data on safety and efficacy of GMCSF in mild-to-moderate Alzheimer’s disease
Timothy D. Boyd, PhD2, Jonathon Woodcock, MD3, Stefan Sillau, PhD3, Vana H. Adame, BS2, Thomas Borges, MD4, Ashesh Thaker, MD4, Brianne Bettcher, PhD4, Joseph Daniels, MS4, Kate Heffernan, BS4, Huntington Potter, PhD2,3
1Rocky Mountain Alzheimer’s Disease Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, 2Linda Cninc Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, 3Department of Neurology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA, 4Department of Radiology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA, 5Department of Neurosurgery, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA
Theme 5. Clinical trials: Cognitive and functional endpoints

P2 - Objectively measured physical activity and cognitive function
Hiroyuki Umegaki1, Taeko Makino2, Kazuki Uemura3, Hiroyuki Shimada4, Xian Wu Cheng4
1MD, PhD Department of Community Healthcare & Geriatrics, Nagoya University Graduate School of Medicine, Aichi, Japan, 2PhD Institute of Innovation for Future Society, Nagoya University, Aichi, Japan, 3Liberal Arts and Sciences, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan, 4Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Obu, Japan, 5PhDb, Masafumi Kuzuya, MD, PhD, Institute of Innovation for Future Society, Nagoya University, Aichi, Japan

P3 - D-Cycloserine improves difficult discriminations in a pattern separation task in Alzheimer’s disease: Implications for dentate gyrus activity and neurogenesis
Pascal J. D. Goetghebeur1, Keith A. Wesnes2, Steven D. Targum3
1Bracket LLC, Reading, UK, 2Wesnes Cognition Ltd, Streatley on Thames, UK, 3Bracket LLC, Boston, US

P8 - A Multicenter, Open-label, 24-week Follow-up Study for Efficacy on Cognitive Function of Donepezil inBinswanger-Type Subcortical Vascular Dementia
Jay Cheol Kwon1, Eung Gyu Kim1, Jae Woo Kim1, Oh Daewon1, Bong Goo Yoo2, Nam Gon Kim1, Nach Cheon Choi1, Seon young Ahn1, Byung Hwa Lee1, Myong Jin Kang1, Dae Seob Choi1, The BKVD Study Group
1Department of Neurology, Changwon Fatima Hospital, Changwon, Korea, The Republic of, 2Samsung Changwon Hospital, Changwon, Korea, The Republic of, 3Gyongbuk National University Hospital

P9 - The Correlation of Diabetic Status, Ischemic and Atrophic Burdens on Brain MRI and Cognitive Decline in Seventy Decade Diabetic Patients with Cognitive Impairment. -1 Year Prospective, Observational Study
Jay Cheol Kwon1, MD, PhD, Kyungsoo Lee1, MD, Yohan Jung1, MD, PhD, Sungiae Cho1, MD, PhD. And Nach-cheon Choi, MD, PhD.
1Changwon Fatima Hospital, Changwon, Korea, The Republic of, 2Samsung Changwon Hospital, Changwon, Korea, The Republic of, 3Gyongsang National University Hospital

P19 - Lanabecestat: Central monitoring of rater performance and error characteristics of efficacy assessments in the AMARANTH study
Alette M. Wessels1, Lisle R. Kingery2, Edward I. Bartolic2, Laura E. Nichell, Jamie A. Mullen1, John R. Sims1
1Bracket LLC, Wayne, PA, USA, 2Boston University School of Medicine, Boston, MA, USA

P25 - Effects of sex, educational background, and CKD grading on cognitive and functional decline in Japanese ADNI study
Atsushi Iwata1, MD, Ryoko Ihara1, MD, Kazushi Suzuki2, MD, Takeshi Iwatsubo, MD, and the Japanese ADNI
1Department of Neurology, The University of Tokyo Hospital, Tokyo, Japan, 2Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital Tokyo, Japan

P26 - A German version of the “Five Word Test” – Discriminating patients with mild cognitive impairment/mild Alzheimer’s disease, healthy controls and patients with depression
Hausner1, MD, Dinu-Biringer R, PhD, Föltz L, MD, PhD
1Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany

P27 - Use of Medications on Transcranial Doppler Vasoreactivity in Mild Cognitive Impairment
Shim YongSoo1, Jung San2
1Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea, 2Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea

P53 - MMSE screening data quality for Alzheimer’s disease studies across countries
Jordan Mark Barbone1, BA, Todd M. Solomon, PhD2, H. Todd Feaster, PsyD1, Macarena Garcia-Valdecasas Coell1, MSc1, & David S. Miller, MD, MA1
1Bracket, Wayne, PA, USA, 2Boston University School of Medicine, Boston, MA, USA

P67 - The presence of identical scoring on the MMSE and ADCS-ADL in Alzheimer’s disease clinical trials using enhanced eCOA devices
Todd M. Solomon1, PsyD1, Jordan Mark Barbone1, BA1, Sarah M. Karas, PsyD1, Danielle T. DiGregorio, PsyD1, Michael R. Maddock1, MA David M. Miller, MD1, H. Todd Feaster, PsyD1
1Bracket, Wayne, PA, USA, 2Boston University School of Medicine, Boston, MA, USA
P71 - The treatment response of Goal Attainment Scaling in relation to goal number in a clinical trial of Alzheimer’s Disease Patients

Kenneth Roockwood, MD, PhD1, Lisa McGarrigle, PhD2
1Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada, 2DIGI Clinical Inc., Halifax, NS, Canada

P74 - Predictive value and test-retest reliability of the tablet-based Brief Assessment of Cognition (BAC App) for assessment of cognition in aging: preliminary findings from an ongoing normative study

Anzalee Khan PhD2,3, Danny Ulshen BA1, Alexandria Atkins PhD2,3, Danela Balentini BA1, Adam Vaughan PhD1, Heather Dickerson PhD1, Brenda L. Plassman PhD1, Kathleen A. Welsh-Bohmer PhD1, Rich Keeve PhD1
1NeuroCog Trials, Durham, NC, USA, 2Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA, 3Duke University, Durham, NC, USA

P77 - Clinical and Amyloid Screen Failure Rates in Episodic Memory Measures of Early AD Trials

Selam Negash, Christopher Weber, Christopher Randolph
1MedAvante-ProPhase, 2Logola University Medical Center

P83 - Determinants of care refusal: from patients suffering from dementia to their caregivers characteristics

Caiestel, Y, Phd, CERDA S, M D
Memory Center, Bagatelle Hospital, Talence, France


Susan Abushakra, MD1, Bruno Vellas MD2, Serge Gauthier MD2, Anton Porsteinsson MD2, Cari Sadowsky MD3, Aidan Power MD1, Larry Shen PhD1, Lu Wang MS3, Tim Lim MS5, John Hey PhD1, Martin Tolar MD PhD1
1*Alzheon, Inc, Framingham, MA, USA, 2University of Toulouse, Toulouse, France, 3McGill University, Montreal, Canada, 4University of Rochester, Rochester, New York, 5Palm Beach Neurology and Nova SE University, Fort Lauderdale, Florida, 6Pharmapace, Inc., San Diego, CA


Ana Espigares, PhD1, Belgena Hernández-Olíasaguer, PhD1, Sonia Moreno-Grau, MSc1, Luca Kleineidam, MSc2,3, Stefanie Heilmann, PhD2,3, Isabel Hernández, MD, PhD1,2, Steffen Wolfsgruber, Dipl.-Psych.1,2, Holger Wagner, MSC1, Maitée Rosende-Roca, MD1, Ana Mauleón, MD1, Liliana Vargas, MD1, Asunción Lafuente, MD1, Octavio Rodríguez-Gómez, MD1, Carla Abdelnour, MD1, Silvia Gil, MD, PhD1, Marta Marquié, MD1, MD2, Miguel A. Santos-Santos, MD1, PhD1, Ángela Sanabria, PhD1, Gemma Ortega, PhD1, Gemma Monté, PhD1, Alba Pérez, MSC1, Marta Ibarria, MSC1, Susana Ruiz, MSC1, Johannes Kornhuber, MD, PhD1, Oliver Peters, MD1, Lutz Fröhlich, MD, PhD1, Michael Hüll, MD1, Martin Scherer, MD1, Tobias Luch, Dipl.-Psych1,2, Steffi Riedel-Heller, MD1, Laura Montorel, MSC1, Pilar Cabahate, PhD1, Mariola Moreno, MSC1, Silvia Prechtler, MSC1, Nuria Aguillera, MSC1, Itziar de Rojas, MSC1, Adela Orellana, PhD1, Montserrat Alegría, PhD1, Sergio Valero, PhD1, Markus M Nöthen, MD1,2, Michael Wagner, PhD1,2,3, Frank Jessen, PhD1,2,3, Wolfgang Maiers, MD1,2,3, Lluis Tàrraga, MSC1, Mercè Boada, MD1, PhD1, Alfredo Ramirez, MD1, PhD2,3,4,5, and Agustin Ruiz, MD1, PhD1,2,3,4,5
1Research Center and Memory Clinic Fundació ACE. Instituto Carlos de Neurociencias Aplicadas, UIC-Barcelona, Spain, 2German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany, 3Department for Neurodegenerative Diseases and Genetic Psychiatry, University Hospital Bonn, Bonn, Germany, 4Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany, 5Institute of Human Genetics, University of Bonn, Bonn, Germany, 6Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany, 7Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany, 8Department of Psychiatry and Psychotherapy, University Clinic Erlangen, Erlangen, Germany, 9Department of Psychiatry, Charité Universitätsmedizin Berlin, Germany, 10Department of Genomic Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, 11Center for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School University of Freiburg, Freiburg, Germany, 12Department of Psychiatry and Psychotherapy, University of Cottbus, Cottbus, Germany, 13Departments of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 14Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany
CTAD 2018

POSTERS PRESENTATION

P143 - Baseline characterization of the European prevention of Alzheimer’s dementia (EPAD) longitudinal cohort study (LCS)
Michael T. Ropachti, PhD, John Harrison, PhD1, Joel Kramer, PsyD, Christopher Randolph, PhD, Jeffrey Kaye, MD2, Bruce Albala, PhD3, Karen Ritchie, PhD4,5
1Strategic Global R&D & Development, Half Moon Bay, USA, 2Mesis Cognition Ltd, UK, 3Alzheimer Center VUmc, Amsterdam, Netherlands, 4Department of Neurology, Memory and Aging Center, University of California at San Francisco, San Francisco, USA, 5Department of Neurology, Loyola University Medical Center, Maywood, USA, 6Neurology and Biomedical Engineering, Oregon Health and Science University, Portland, USA, 7Institut National de la Santé et de la Recherche Médicale, U1061 Neuropsychiatrie, Montpellier, France, 8Faculty of Medicine, University of Montpellier, Montpellier, France, 9Center for Dementia Prevention, University of Edinburgh, Edinburgh, UK

P144 - Two distinct modelling approaches of cognitive decline and time to diagnosis of MCI/dementia to inform study design and improve risk prediction in preclinical Alzheimer’s Disease
Angelita Caputo, PhD1, Ana Grafl, MD2, Cristina Lopez Lopez, PhD3, Valery Risson, PhD2, Giulia Lestini, PhD4, Neva Coello, PhD4, Amy Racine, PhD5, Ines Paule, PhD6, Luyuan Qi, PhD6, Helene Karcher, PhD6
1Novanis Pharma AG, Basel, Switzerland, 2Analytica Laser, a Certara company, Paris, France, 3Analytica Laser, a Certara company, London, UK

P146 - Comparison of sleep measurements from actigraphy to self-reported sleep diaries
Kirsì Kinnunen, PhD1, Richard Joules, PhD1, Janet Munro, MPH2, Iain Simpson PhD2, Robin Wolz2, PhD2, Yves Dauvilliers, MD PhD3
1XICO Pte, London, UK, 2Imperial College London, London, London, UK, 3Sleep Unit, Department Neurology, Centre Hospitalier Universitaire, Montpellier, INSERM U661, France

P148 - Advancing Clinical and Biomarker Research in AD: The LEAD Study
Liana G. Apostolova, MD, Paul Alsen, MD, Ani Eloyan, PhD, Anne Fagan, PhD, Tatiana Foroud, PhD, Constantine Gatsonis, PhD, Clifford Jack, MD, Joel Kramer, PsyD, Robert Koepp, PhD, Andrew Saykin, PsyD, Arthur Toga, PhD, Prashanthi Vemuri, PhD, Gregory Day, MD, MSc, Neill Graff-Radford, MD, Lawrence Honig, MD, David Jones, MD, Sterling Johnson, PhD, Joseph Masdeau, MD, Mario Mendez, MD, Chiadi Onyike, MD, Emily Rogalski, PhD, Steve Salloway, MD, David Wolk, MD, Thomas Wingo, MD, Maria Cantillo, PhD, Brad Dickerson, MD, Gil Rabinovic, MD

P149 - Measuring Pre-Clinical Cognitive Decline over Time: Separating and Combining Alzheimer’s Specific Decline and Cognitive Decline Related to Aging in Cognitive Composite Scores
Suzanne Hendrix, PhD1, Noel Ellison, MS1, Jessica B. Langbaum, PhD1,2, Kewei Chen, PhD1,2, and David A. Bennett, MD4
1Pentara Corporation, Milletree, UT, USA, 2Arizona Alzheimer’s Consortium, Phoenix, AZ, USA, 3University of Arizona, Tucson, AZ, USA, 4Rush University, Chicago, IL, USA

Late Breaking Posters

LBP41 - Effects of 2-year walnut supplementation on cognitive decline in healthy elders: The Walnuts And Healthy Aging (WAHA) study
Nina Coll-Padrò,1 Alexi Sala-Vila2, Cinta Valls-Pedret2, Mercè Serra-Mir23 Montserrat Cofán23, Irene Roth2, Tania Freitas-Simoes2, Mónica Domènec1, Lidia Vaqué-Alcàzar2, David Bartrés-Faz2, Sujatha Rajaram2, Joan Sabaté2, Emilio Ros2,3
1Alzheimer Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 2Lipid Clinic, Endocrinology and Nutrition Service, Hospital Clinic, Barcelona, Spain, 3CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain, 4Institut de Neurociències i Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain, 5School of Public Health, Loma Linda University, Loma Linda, CA, USA

LBP42 - ADCOMS: a post-hoc analysis using data from the LipiDiDiet trial in prodromal Alzheimer’s disease
Suzanne B. Hendrix, PhD1, Hilkka Soininen, MD, PhD2,3, Pieter Jelle Visser, PhD4,5, Alina Solomon, MD, PhD2,3, Miia Kivipelto, MD, PhD2,3, Tobias Hartmann, PhD6,7 on behalf of the LipiDiDiet clinical study group
1Pentara Corporation, Salt Lake City, UT, USA, 2Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, 3Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland, 4Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands, 5Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands, 6Department of Clinical Geriatrics, NIVD, Karolinska Institute, Huddinge, Sweden, 7Department of Experimental Neurology, Saarland University, Saarland University Hospital, Huddinge, Sweden, 8Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University, Homburg, Germany, 9Department of Experimental Neurology, Saarland University, Homburg, Germany
LBP43 - Intraventricular Injection of Human Umbilical Cord Blood Mesenchymal Stem Cells in Patients with Alzheimer’s Disease Dementia: A Phase I Clinical Trial
Hee Jin Kim, MD, PhD1,2, Kyung Rae Cho, MD2, Hyemin Jang, MD, PhD1,2, Jung Il Lee, MD, PhD2,2, Seongbeom Park, MS1,2, Soo Jin Choi1, Sung Tae Kim, MD, PhD2, Seung Hwan Moon, MD, PhD2, Kyung-Han Lee, MD, PhD2, Sang Won Seo, MD, PhD2,2, Duk L. Na, MD, PhD1,2
Departments of 1Neurology, 2Neurosurgery, 3Radiology, and 4Nuclear Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 5Neuroscience Center, Samsung Medical Center, Seoul, Korea, 6Biomedical Research Institute, MEDIPOST Co., Ltd, Seoul, Korea, 7Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea, 8Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea

LBP44 - Exploratory analysis of results from the NILVAD trial suggest benefit in very mild AD subjects
Michael Mullan, MBBS, PhD1,2, Laila Abdullah, PhD2, Heather Langlois2, Fiona Crawford, PhD1,2, Anders Wallin, MD3, Suzanne Hendrix, PhD4, Kaj Blennow, MD, PhD5, Brian Lawlor, MBBS6. The NILVAD consortium
1Archer Pharmaceuticals, Sarasota, FL, USA, 2Roskamp Institute, Sarasota, FL, USA, 3Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden, 4Pentara Corporation, Salt Lake City, UT, USA, 5Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden, 6Trinity College Dublin, Dublin, Ireland

LBP45 - Can digital footprints capture clinically relevant gait endpoints in non-clinically setting: a Proof of Concept?
Marie Mc Carthy1, Crystal Gon2
1ICON PLC, Dublin, Ireland, 2Trinity College Dublin, Ireland

LBP46 - Using the power of Dementias Platform UK (DPUK) cohorts to investigate the longitudinal effects of childhood adversity on adult cognition and health outcomes: implications for cognitive change and dementia outcomes
Sarah Bauermeister, PhD and John Gallacher, PhD
University of Oxford, Department of Psychiatry, Oxford, UK
P6 - Evaluation of titers of antibodies against peptides of subunits NRI and NR2B of glutamate receptor by enzyme-linked immunosorbent assay in psychiatric patients with anti-thyroid antibodies
Takahiro Ikura, MD, PhD, Yotohamacity University Psychiatry

P14 - Anosognosia in Mild Cognitive Impairment and Dementia
Dong Won Yang1, Ahro Kim1 Dong Woo Lee2, Hyun Jeong Han3, Jee Hyang Jeong3, Jun Hong Lee4, Jun-Young Lee5, Kee Hyung Park5, Kyung Won Park6, SangYun Kim7, Seong Hye Choi8, Young Chul Youn9
1Department of Neurology, Catholic University of Korea, Seoul, Korea, 4Department of Psychiatry, Inje University Sanggye Paik Hospital, Seoul, Korea, 2Department of Neurology, Myongji Hospital, Goyang, Korea, 3Department of Neurology, Gachon University Gil Hospital, Incheon, South Korea, 4Department of Neurology, Catholic University of Korea, Seoul, Korea, 5Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea, 6Department of Neurology, Myongji Hospital, Goyang, Korea, 7Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea, 8Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea, 9Department of Psychiatry and Neurosciences Research Institute, Seoul National University College of Medicine & SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, 10Department of Neurology, Catholic University Gil Hospital, Incheon, South Korea

P24 - Clinical correlates of types of memory complaints in mild cognitive impairment
Seon Young Ryu1, MD, PhD1, Sang Bong Lee1, MD, PhD1, Taeh Jun Lee2, MD1, Yi Jin Jung1, MD, PhD1
1Neurology Department, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, South Korea

P29 - A comparison between brief episodic memory and semantic memory tasks within a screening test for mild cognitive impairment
Evelina Vallocia Eds1, Katherine Kruczek, MS1
Bioclinica Research, The Villages, FL, USA

P33 - Comparative evaluation of tests for the cognitive dysfunction screening in the national medical check-up
Ahro Kim1, Dong Won Yang1, Dong Woo Lee2, Hyun Jeong Han3, Jee Hyang Jeong3, Jun Hong Lee4, Jun-Young Lee5, Kee Hyung Park5, Kyung Won Park6, SangYun Kim7, Seong Hye Choi8, Young Chul Youn9
1Department of Neurology, Seoul St. Mary’s hospital, Catholic University of Korea, Seoul, Korea, 2Department of Psychiatry, Inje University Sanggye Paik Hospital, Seoul, Korea, 3Department of Neurology, Myongji Hospital, Goyang, Korea, 4Department of Neurology, Gachon University Gil Hospital, Incheon, South Korea, 5Department of Neurology, Catholic University of Korea, Seoul, Korea, 6Department of Neurology, Catholic University of Korea, Seoul, Korea, 7Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea, 8Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea, 9Department of Psychiatry, Seoul National University Boramae Hospital, Seoul, Korea, 10Department of Neurology, Gachon University Gil Hospital, Incheon, South Korea

P34 - A multicentre, pilot study to evaluate an Augmented Reality test (ALTOIDATM) for mild cognitive impairment detection
Mircea Balasa1, MD, PhD1, 2Adrià Tort-Merino, MSc1, Ioannis Tamanas, PhD23, David Bartrès-Faz, PhD4, Rory Boyle, MSc5, Laura Rai MSc5, Rob Whelan, PhD56, Raquel Sanchez-Valle, MD, PhD1
1Alzheimer’s Disease and other Cognitive Disorders Unit, Neurology Department, Hospital Clinic, Barcelona, Spain, 2Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland, 3Altaoida AG, Lucerne, Switzerland, 4Department of Medicine, Faculty of Medicine and Health Sciences, University of Barcelona, 5School of Psychology, Trinity College Dublin, Dublin, Ireland

P41 - Cognitive impairment under treatment with 2nd and 3rd generation antihistamines in elderly subjects
Georg Adler1, Nadja Baumgart1
1Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany

P42 - Using Bayesian models to method normative CANTAB cognition data across adulthood
Pasquale Dent1, Elizabeth Baker1, Jack Cotter1, Francesca Cormack1, Jennifer H Barnett12
1Cambridge Cognition Limited, Cambridge, UK, 2Cambridge University, Cambridge, UK

P47 - Predicting the course of Alzheimer’s
Samuel Izadi1, PhD1, Dan Li1, PhD1, Wesley Thompson, PhD2, Michael S. Raffi3, MD, PhD4, Paul S. Aisen4, MD1, and Michael C Donohue5, PhD1
1ARI, University of Southern California, San Diego, CA, United States, 2Department of Family Medicine and Public Health, University of California, San Diego, USA, 3Department of Statistics, University of Gana, Legon-Accra, Ghana

P48 - Impaired delayed recall on the International Shopping List Task predicts amyloid positivity and longitudinal decline in CDR-SB scores in MCI
Sharon Rosenzweig-Lipson, PhD1, Richard Mohs, MD1, Paul Maruff, PhD2, Michela Gallagher, PhD3, and Arnold Babker, PhD3
1Agencebo, Inc, Baltimore, MD, USA, 2Cognitive, Ltd, Melbourne, Victoria, Australia, 3Johns Hopkins University, Baltimore, MD, USA

P49 - MMSE screening data quality for Alzheimer’s disease studies across countries
Jordan Mark Barbone, BA1, Todd M. Solomon, PhD1, H. Todd Feaster, PsyD1, Macarena Garcia-Valdecasas Colell, MSc1, David S. Miller, MD, MA1
1Brachet, Wayne, PA, USA, 2Boston University School of Medicine, Boston, MA, USA, 3Brachet, Reading, UK
P50 - Affective variability predicts cognitive fluctuation and decline in older adults
Edward Zamrini, MD, Michael Malek-Ahmadi, PhD, Kathy O'Connor, Sharon Schofeld
Banner Sun Health Research Institute, Sun City, USA, Banner Alzheimer’s Institute, Phoenix, USA

P51 - Validation of the geriatric depression scale in the elderly Korean with Alzheimer’s disease
Moon Ho PARK, MD, PhD, Do-Young KWON, MD, PhD
Department of Neurology, Korea University Ansan Hospital, Ansan, South Korea

P52 - Can TMT-black and white predict the white matter hyperintensity of MRI in the community based elderly?
Young Chul Youn, MD, PhD
Neurology Department, Chung-Ang University College of Medicine, Seoul, Korea

P55 - CANTAB tests predict change in global functioning in patients with amnestic mild cognitive impairment
Elizabeth Bater PhD, Peter Annas PhD, Giovanni B. Frisoni, MD, PhD3, David Bartres-Faz, MD, PhD4, Beatriz Bosch PhD5, Jose Luis Molinuevo, MD, PhD6, Mira Dedic, MD, PhD7, Francesca De Anna8, Lucilla Parnetti, MD, PhD9, Nicola Salvadori PhD10, Jens Wiltfang, MD, PhD11, Flavio Nobili, MD12, Nicola Girtner, Psy.D13, Peter Schönhödt, MD, PhD14, Paolo M. Rossini, MD, PhD15, Paolo Chiovenda, MA16, Pierre Payoux, MD, PhD17, Andrea Sorcilli, MD, PhD18, Marco Salvatore, PhD19, Magda Tsolaki, MD, PhD20, Jill C. Richardson, PhD21, Régis Bordet, MD, PhD22, Olivier Blin, MD, PhD23, Gianluigi Forloni24 on behalf of the PharmaCog Consortium

P63 - Validating simulated cognition trajectories based on ADNI against trajectories from the National Alzheimer’s Coordinating Center (NACC) dataset
Ali Tafazzoli, PhD, Josh Weng, PhD1, Kelly Sutton, PhD2, Michal Lithiewicz, MSC3, Ameya Chavan, BS4, Mira Krotneva, MSC5, Anuraag Kansal, PhD6
Evidera, Bethesda, MD, USA, Evidera, Waltham, MA, USA, Evidera, London, UK, Evidera, Montreal, Canada

P68 - Recruitment using the DCTclockTM
Daniel Lawler MD, Stephen Thein PhD
Pacific Research Network Inc., San Diego, CA, USA

P70 - Strategy or symptom: semantic clustering and risk of Alzheimer’s disease
Jamie Ford, MSC1, Bang Zheng, MSC, MD1, Barbara Hurtado, M.A, CPsychol1, Chi Udeh-Momoh, MSC, PhD2, Geraint Price, MSC, D Clin Psy3
Imperial College London, UK

P72 - Tau is associated with longitudinal memory decline in healthy subjects: the need for an early detection of subtle cognitive changes
Adria Tort-Merino, MSC1, Jaume Olives, MSC1, Maria Leon, MSC1, Claudia Peñaloza, PhD2, Natalia Valech, MSC3, Petra Grönholm-Nyman, PhD3, Pablo Martinez-Lage, MD, PhD4, Juan Fortea, MD, PhD4,5, Jose Luis Molinuevo, MD, PhD6, Raquel Sánchez-Valle, MD, PhD6, Matti Laine, PhD3, Antoni Rodríguez-Fornells, PhD3,5,6, Lorena Rami, PhD8

P75 - Flunks and flukes: recognising unrepresentative performance on cognitive tests
Geraint Price, D Clin Psy1, Bowen Su, MD2
Imperial College London, UK
P87 - Assessing decline in visuospatial working memory associated with subjective cognitive impairment using a tablet-based measure of hippocampal-dependent learning
Alexandra S. Atkins1, Anzalee Khan1,2, Daniel Ulschen3, John Harrison1,2, Brenda L. Plassman1, Kathleen A. Welsh-Bohmer2 & Richard S.E. Keefe1,4
1NeuroCog Trials, Durham, NC, 2Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, 3Alzheimer Center, VUmc, Amsterdam, The Netherlands, 4 interrupted, King's College, London, UK, 5Duve University Bryan ADCRC, Durham, NC, 6Duve University Medical Center, Durham, NC

P88 - Severe cognitive impairment in older adult heart failure patients: Preliminary findings from the Deus ex Machina study
Emilia Moreira1, Psy, MPH, PhD1, Sónia Martins, Psy, PhD2, Luís Filipe Azevedo, MD, PhD3, José SilvaCardoso, MD, PhD1,6, Lia Fernandes, MD, PhD1,6
1Center for Health Technology and Services Research/CINTESIS, Faculty of Medicine, University of Porto, Portugal, 2Department of Clinical Neurosciences and Mental Health, Faculty of Medicine, University of Porto, Portugal, 3Department of Community Medicine, Information and Health Decision Sciences/MEDCIDS, Faculty of Medicine, University of Porto, Portugal, 4Department of Medicine, Faculty of Medicine, University of Porto, Portugal, 5Department of Cardiology S. João Hospital Center, Porto, Portugal, 6Clinic of Psychiatry and Mental Health, S. João Hospital Center, Porto, Portugal

P89 - The effect of dizziness in patients with cognitive impairments
Seunghee Na1, M.D., In-Uk Song, MD, PhD
Department of Neurology, Incheon St. Mary's Hospital, the Catholic University of Incheon, Korea

P151 - Selection of depression-specific dementia cases with replication in two cohorts
Donald R. Royall, MD1,4, Raymond F. Palmer, PhD1,2
1Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, 2Department of Medicine, UTHSCSA, San Antonio, Texas, USA, 3Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA, 4South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P152 - Selection of depression-specific dementia cases with replication in two cohorts
Donald R. Royall, MD1,4, Raymond F. Palmer, PhD1,2
1Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, 2Department of Medicine, UTHSCSA, San Antonio, Texas, USA, 3Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA, 4South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P153 - Assessment and speech-language intervention program in Non-Fluent Primary Progressive Aphasia: A case study
Beatriz Valles-González1, Vicent Rosell-Clari2
1Speech and Language Pathology Clinic. Lluís Alcanyís Foundation-Universitat de Valencia, 2Basic Psychology Department. Universitat de Valencia

P154 - Prediction of APOE ε4 Burden from Cognitive Assessment
Royal DR1,2, Palmer RF1 for the Alzheimer’s Disease Neuroimaging Initiative1
1Departments of Psychiatry, 2Medicine, Family & Community Medicine, The University of Texas Health Science Center at San Antonio and the 3South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC)

P155 - Could Telemedicine improve neurocognitive disorders detection and diagnosis in nursing home? 
Armelle Lepere-Desplanches1, Isabelle Hauger1, Sylvain Gaulier1, Antonis Politis2, Shima Mehrabian3, Audrey Maillet1, Pierre Krolak-Salmon1
1Clinical and Research Memory Centre, Lyon Institute for Elderly, Hospices Civils de Lyon, Inserm UMR028, CNRS UMR 5292, Lyon University, France, 2Résidence Talanssa, Talence, France, 3National and Kapodistrian University of Athens, Athens, Greece, 4Clinic of Neurology, UH “Alexandrovskia”, Medical University, Sofia, Bulgaria

P156 - Cognitive Blachouts in Mild Cognitive Impairment of the Amnestic Type and mild Alzheimer’s Dementia
Georg Adler1, Agniesz Marczat, Jana Binder, Katharina Gnosa
Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany

P157 - Feasibility of the neuropsychological battery camcong-ds for the detection of cognitive decline in people with down syndrome
Laura Videla1,2, Bessy Benejam1, María Carmona-Iraguir3, Susana Fernández1, Isabel Barroeta1,2, Sebastián Videla2, Alberto Lled2,3, Rafael Blesa2, Juan Fortea3
1Alzheimer Unit - Donau, Donauf Medical Center, Fundación Catalana Sindrome de Down, 2Memory Unit of the Neurology Service of the Hospital de la Santa Creu and Sant Pau, Biomedical Research Institute of Sant Pau, Universitat Autònoma de Barcelona, 3Central Biomedical Research Center (CIBERNED)

P158 - Distinct patterns of cognitive decline between early-onset Alzheimer’s disease and late-onset Alzheimer’s disease
Adrià Tort Merina1, MSc1, Jaume Olives, MSc1, Neus Falgás, MD1, Mircea Balasa, PhD1, Magda Castellvi, MSc1, Sergi Borrego, MD1, Beatriz Bosch, PhD1, Maria León, MSc1, Ana Salinero, MSc1, Guadalupe Fernández, RN1, Anna Antonell, PhD1, Raquel Sánchez-Valle1, MD, PhD1, Lorena Rami, PhD1, Albert Lladó, MD, PhD1
1Alzheimer’s Disease and other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain
PI59 - High level of plasmatic amyloid Aβ 1-40 increase the risk of cognitive decline in 3C study with 14 years of follow-up
Audrey Gabrielle, MD, Ph.D2,3, Laure-Anne Gutierrez, MSc2,3, Thibault Mura M.D, Ph.D2,3, Jean-François Dartigues, Ph.D2,3, Olivier Rouaud, MD2, Jean-Charles Lambert Ph.D3,4, Catherine Helmer, Ph.D3,4, Claudine Bent M.D, Ph.D3,4
1Memory Research and Resources Center, Montpellier University Hospital, Montpellier, 2Inserm U1061, La Colombière Hospital, Montpellier, 3University of Montpellier, MUSE University, Montpellier, 4Bordeaux University, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France, 5CHU Bordeaux, Department of Public Health, F-33000 Bordeaux, France, 6CHRU Dijon, Centre Mémoire Ressources et Recherche, Dijon, France, 7CHRU de Lille, Lille, France, 8INSEERM U744, Lille, France, 9Institut Pasteur de Lille, Lille, France, 10Université de Lille Nord de France, Lille, France

PI62 - Using graphical hierarchical bayesian cognitive process models applied to common memory tests to detect ad pathology within normal subjects
William R. Shankle, MS, MD2,3, Junho Hara, PhD1,3, Jason R. Boch, MA1, Denis Fortier, MBA1, Tushar Mangrola, MS1, Michael Lee, PhD2, Gregory E. Alexander, PhD2, William H. Batchelder, PhD2, Ronald C. Petersen, MD, PhD4, Walter Kremers, PhD4
1Medical Care Corporation, Newport Beach, CA, USA, 2Dept. of Cognitive Sciences, University of California at Irvine, Irvine, CA, USA, 3Pickup Family Neuroscience Institute, Hoag Memorial Hospital, Newport Beach, CA, USA, 4Mayo Clinic, Rochester, MN, USA

Late Breaking Posters

LBP47 - Strategic Memory Alzheimers Rehabilitation Training (SMART) Memory Program for Amnestic Mild Cognitive Impairment (aMCI): Reporting the Results of a Randomized Clinical Trial
John W. DenBoer, Ph.D., SMART Brain Aging, Inc

LBP48 - Memory errors of commission rather than errors of omission discern aging and early Alzheimers disease
Matthias W. Riepe, MD, Claudia Lanza, PhD, Karolina Sejunaite, MS
Department of Psychiatry and Psychotherapy II, Mental Health & Old Age Psychiatry, Ulm University, Ulm, Germany

LBP49 - Standard cognitive assessment in the era of biomarkers and disease-modifiers
Marina Boccardi, PsyD, PhD1,2, Stefano Cappa, MD, PhD3, Bruno Dubois, MD4, Jean Georges5, Matthias Kliegel, PsyD, PhD6, Bengt Winblad, MD, PhD7, David Salmon, PhD1, Giovanni Frisoni, MD1,2, Andreas Monsch, PsyD, PhD8, for the Tash Force for Harmonizing Neuropsychological Assessment for Dementing Neurodegenerative Disorders
1LANVIE, Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland, 2IRCCS S.Giovanni di Dio, Fatebenefratelli, Brescia, Italy, 3Dementia Research Center, Hôpital Pléiade-Salpétrière, Paris, France, 4Alzheimer Europe, 5Laboratory of Cognitive Aging, University of Geneva, Geneva, Switzerland, 6Karolinska University Hospital, Stockholm, Sweden, 7Department of Neurosciences, University of California San Diego School of Medicine, United States, 8University of Basel, Basel, Switzerland

LBP50 - Lanabecestat: Rater performance and error characteristics of efficacy assessments in the DAYBREAK-ALZ study
Alette M. Wessels, PhD1, Jordan Mark Barbone, BA2, Danielle T. DiGregorio, PsyD2, David S. Miller, MD, MA2, Jamie A. Mullen, MD1, John R. Sims, MD2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Brochet, Wayne, PA, USA, 3AstraZeneca Pharmaceuticals, Cambridge, MA, USA

LBP51 - iPSC model of CHRFAM7A effect on a7 nicotinic acetylcholine receptor function may explain the translational gap in drug development
Ivanna Ilnatovych1, Tapan Nayak1, Aya Ouf1, Norbert Sule2, Barbara Birhaya1, Lee Chaves1, Anthony Auerbach1
1SUNY at Buffalo, 2Roswell Park Cancer Institute

LBP52 - Effects of Age and CSF measures of Tau on Mnemonic Discrimination of Objects and Scenes in Medial Temporal Lobe Pathways
David Berron, PhD1,2, Arturo Cardenas-Blanco, PhD1, Daniel Bittner, MD1, Coraline D. Metzger, MD, PhD1, Annika Spottke, MD2, Michael Heneka, MD1, Klaus Fließbach, MD2, Anja Schneider, MD1, Stefan J. Teipel, PhD, MD1,2, Michael Wagner, PhD3,4, Oliver Specht, Prof. Dr.5, Frank Jessen, MD, Prof. Dr.6,7, Emrah Düzel, MD5,6,7 and the DELCODE study group
1Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden, 2University Hospital Magdeburg, Magdeburg, Germany, 3German Center for Neurodegenerative Diseases, Magdeburg, Germany, 4German Center of Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany, 5Department of Neurology, University Hospital of Bonn, Bonn, Germany, 6German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany, 7Department of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany, 8Department of Neurology, University Hospital of Bonn, Bonn, Germany, 9German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany, 10Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany, 11Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany, 12Department of Psychosomatic Medicine, University Hospital Bonn, Bonn, Germany, 13Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany, 14Department of Biomedical Magnetic Resonance, Otto-von-Guericke University, Magdeburg, Germany, 15Department of Psychiatry, University Hospital Cologne, Cologne, Germany
Theme 7. Behavioral disorders and clinical trials

P32 - Effect of memantine on behavioral and psychological symptoms of dementia (BPSD) of Alzheimer’s disease - Study of changes in cerebral blood flow by spect imaging

Aims

Kiyoshi Kanaya1, Shine Abe2
1MD, Geriatric medicine, Tokyo Medical University Hachioji medical center, 2MD, Geriatric medicine, Tokyo Medical University Hachioji medical center

P37 - Clusterization of behavioral and psychological symptoms of dementia (BPSD)

Timofey L. Galanin, MD, PhD, Anton Y. Bespalov, MD, PhD1, Hans J. Moebius, MD, PhD2
1EXCIVA, Am, Germany, 2Valdman Institute of Pharmacology, Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia

P43 - The effect of dizziness in patients with cognitive impairments

Seunghee Na, MD, In-Uk Song, MD, PhD
Department of Neurology, Incheon St. Mary’s Hospital, the Catholic University of Korea, Incheon, Korea

P163 - A multicenter, randomized trial to assess efficacy of Therapeutic Intervention Program for Dementia Caregivers (I-CARE)

Jihye Hwang, MD, PhD1, Geon-Ha Kim, MD, PhD1, Hae-Ri Na, MD, PhD1, Soo-Jin Cho, MD, PhD1, Kyung-Ho Yu, MD, PhD1, Do Hoon Kim, MD, PhD1, Jae-Hong Lee, MD, PhD1, Seong-Hye Choi, MD, PhD1
1Department of Neurology, Keimyung University School of Medicine, 2Department of Neurology, Keimyung University School of Medicine, 3Department of Neurology, Bobath Memorial Hospital, 4Department of Neurology, Bobath Memorial Hospital, 5Hallym University School of Medicine, 6University of Ulsan College of Medicine, Department of Neurology, 7Inha University School of Medicine

Late Breaking Posters

LBP53 - Prevalence of obstructive sleep apnea in Alzheimer’s disease patients

Anna Carnes, PhD1, Carme Jorge1, MD, Benitez ID2, Faride Dakterzada1, Olga Minguez2, Raquel Huerto1, Montse Pujol1, MD, PhD, Anna Gaeta, MD2, Alfonso Arias1, MD, Aurora Gibert1, Manuel Sanchez de la Torres1,2, MD, PhD, Ferran Barbé2,3, MD, PhD, Gerard Piñol-Ripoll1, MD, PhD
1Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria Lleida (Spain), 2-Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain, 3Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain
Theme 8. Health economics and clinical trials

P17 - Effect of physical activity on the progression of Alzheimer’s disease: the CREDOS study
Seong Hye Choi1, Jee Hyang Jeong2, Eun-Joo Kim3, Kyung Won Park4, Bora Yoon5, Soo Jin Yoon6, Yang-Ki Minn7, Young Ju Suh8
1Department of Neurology, Inha University School of Medicine, Incheon, South Korea, 2Department of Neurology, Ewha Womans University School of Medicine, Seoul, South Korea, 3Department of Neurology, Pusan National University School of Medicine, Busan, South Korea, 4Department of Neurology, Dong-A Medical Center, Dong-A University College of Medicine, Busan, South Korea, 5Department of Neurology, College of Medicine, Konkuk University, Daejeon, South Korea, 6Department of Neurology, Eulji University School of Medicine, Daejeon, South Korea, 7Department of Neurology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea, 8Department of Biomedical Sciences, Inha University School of Medicine, Incheon, South Korea

P40 - The Survey for Current State and Dognition of Activities of Daily Living in Korean dementia patients
Kee Hyung Park, MD, PhD1, Chan-Nyoung Lee, MD, PhD2, Hojin Choi, MD, PhD3
1Department of Neurology, Gachon University, Gil Medical Center, Incheon, Korea, 2Department of Neurology, Korea University College of Medicine, Seoul, Korea, 3Department of Neurology, Hanyang University Guri Hospital, Guri, Korea

P58 - Young onset diseases care pathways. Parcours des malades Alzheimer et apparentés jeunes - PARMAAJ
Adeline Rollin-Sillaire, MD1,2, Brigitte Leprince3, Catherine Adnet-Bonte, MD2, Laetitia Breuilh, PhD2, Florence Pasquier, MD, PhD2
1Centre National de Référence des Malades Alzheimer Jeunes, Neurology Department, Centre Hospitalier Universitaire de Lille, France, 2Excellence Laboratory DISTALZ, Inserm U1171, Univ Lille, 3Meotis, Centre Hospitalier Universitaire de Lille, France

P164 - Dutch online registry for recruitment of participants for dementia studies
Marissa D. Zwan, PhD1, Derek Flenniken2,3, Shannon Finley, MA2, Aaron Ulbricht2,3, Rachel Nosheny, PhD2,3, Wiesje M. van der Flier, PhD1, Philip Scheltens, MD, PhD1, Diana Truran-Sacrey2, Michael W. Weiner, MD2,3, Niels D. Prins, MD, PhD1
1Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands, 2Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, San Francisco, USA, 3UCSF Department of Radiology and Biomedical Imaging, San Francisco, USA
Theme 9. Epidemiology and clinical trials

PI7 - Awareness of Alzheimer’s dementia as their own disease in Asian Countries
San Jung, YongSoo Shim, SangYun Kim

Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea, Department of Neurology, College of Medicine, The Catholic University of Korea, Bucheon St. Mary's Hospital, Seoul, Korea, Department of Neurology, Seoul National University College of Medicine & Clinical Neuroscience Center, Seoul National University Bundang Hospital, Seoul, Korea

P38 - Subjective memory complaints are related to the social participation and leisure activities: TOyoake Integrated Care Study (TOICS)
Hajime Takechi, MD, PhD1, Atsira Tsuzuki, RPT, DMSc2, Komalti Matsumoto, Ms3, Hiroyuki Nishiyama, Mr4, MasatoshI Ogawa, Mr4, Yoshikiiyo Kanada, RPT, DMSc2

1Department of Geriatrics and Cognitive Disorders, School of Medicine, Fujita Health University, Aichi, Japan, 2Faculty of rehabilitation, School of Health Science, Fujita Health University, Aichi, Japan, 3Department of community care, Toyoake city municipal office, Aichi, Japan, 4Gyosei Corporation, Tokyo, Japan

P46 - Alzheimer’s disease drug development pipeline: 2018
Jeffrey Cummings, PhD4, Caram Lee, PharmD1, Aaron Ritter, MD1, Kate Zhong, MD2

1Cleveland Clinic Lau Ruo Center for Brain Health, Las Vegas, NV, USA, 2Global Alzheimer Platform, Washington, D.C., USA

P165 - Association between amyloid status and multiple chronic diseases in European Prevention of Alzheimer’s Dementia (EPAD): network and cluster analyses
Lucy E Stirland, MBChB, MRCPsych1, Tom C Russ MBChB, PhD, MRCPsych2, Graciela Muniz Terrera, PhD3, Craig W Ritchie MBChB, PhD, MRCPsych1

Centre for Demenaria Prevention, University of Edinburgh, Edinburgh, UK, 2Alzheimer Scotland Dementia Research Centre, Edinburgh, UK

P166 - Concord-AD: An International Network of Cohorts for Better Understanding Alzheimer’s Disease
Samantha C Burnham, PhD1, Preciosa M Coloma, MD, PhD2, Teresa J Christainson3, BS, Jean-Francois Dartigues, MD, PhD4, Rachelle Doody, MD, PhD5, Oshar Hansson, MD, PhD1, Catherine Helmer, MD, PhD4, Joseph S Kass, MD, JD1, Colin L Masters, MD6, Sebastian Palmqvist, MD, PhD7, Valory N Pavlik, PhD8, Ronald C. Petersen, MD, PhD9,10, Daniel Wang, PhD9,10, Rosebud O. Roberts, MB ChB10, MS11, Maria Vassilakid, MD, MPH, PhD6, Barbara Schauble12 and Mary Sano13,14,15

1Centre for Dementia Prevention, University of Edinburgh, Edinburgh, UK, 2Alzheimer Scotland Dementia Research Centre, Edinburgh, UK

P167 - Cognitive and brain structural correlates of insomnia symptoms in middle-aged healthy adults
Oriol Grau-Rivera1, Juan Domingo Gispert2, Grégory Operto1, Carles Falcón1, Raffaele Cacciaglia1, Gonzalo Sánchez-Benavides2, Anna Bugulat1, Nina Gramunt3, Gemma Salvador1, Marc Suárez-Calvet4, Carolina Minguillón1, Karine Fauria1, José Luis Molinueto2,3

1BarcelonaBrain Research Center, Catalonia, Spain, 2Centro de Investigación Biomédica en Red de Bioenergética, Biomateriales y Nanomedicina (CIBER-BBN), Zaragoza, Spain, 3CIBER Fraildidad y Envejecimiento Sustentable (CIBERFES), Madrid, Spain, 4Institut d'Investigacions Biomèdiques August Pi i Sureda (IDIBAPS), Barcelona, Catalonia, Spain

P168 - A Phase II randomized clinical trial of high-dose versus standard-dose Vitamin D3 in an ethnically diverse sample of older adults
John Olichney, MD1,2, Charlie DeCarli, MD1,2, Joshua W Miller, PhD3, David Johnson, PhD3, Sarah Tomaszewski-Farias, PhD1, Bruce Hammoch, PhD3, Brittany Dugger, PhD4, Lee-Way Jin, MD, PhD5, Mary McPhail-Ciufo, DO1, Robert Soohoo, BS6, Dan Mungas, PhD1, Danielle Harvey, PhD8

1Neurology, Department, University of California Davis, Sacramento, CA, USA, 2Department of Nutritional Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ, 3Department of Entomology & Comprehensive Cancer Center, University of California Davis, Davis, CA, USA, 4Pathology Department, University of California Davis, Sacramento, CA, USA, 5Psychology Department, University of California Davis, Davis, CA, USA, 6Department of Public Health Sciences, University of California Davis, Davis, CA, USA

Late Breaking Posters

LBP54 - Psychometric methodologies to increase scale-reliability in dementia-focused epidemiology: Outcomes from the European Prevention of Alzheimer’s Disease Study and UK Biobank
Sarah Bauermeister, PhD and John Gallacher, PhD

University of Oxford, Department of Psychiatry, Oxford, UK
LBP55 - STOPBANG and Berlin Questionnaire as screening tools to identify obstructive sleep apnea in Alzheimer’s disease
Anna Carnes, PhD1, Benitez ID2, Faride Dakterzada1, Olga Minguez2, Raquel Huerto1, Montse Pujol2, MD, PhD, Anna Gaeta, MD2, Alfonso Arias1, MD, Aurora Gibert1, Manuel Sanchez de la Torres1, MD, PhD, Ferran Barbé2,3, MD, PhD, Gerard Piñol-Ripoll2, MD, PhD
1Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria, Lleida, Spain, 2Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain, 3Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain

LBP56 - Exposure to benzodiazepines and development of Alzheimer’s disease: a cohort study in a Health Region of Catalonia between 2002 and 2015
Carnes A1, Torres-Bondia, FI1, de Batlle J2, Piñol-Ripoll, G1
1Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria Lleida, Spain, 2Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain
Theme 10. Animal model and clinical trials

**P102** - Concussive head injury exacerbates Alzheimer’s disease brain pathology. Superior neuroprotection by Co-administration of TiO2 nanowired Cerebrolysin together with antibodies to neuronal nitric oxide synthase and mesenchymal stem cells

Hari Shanker Sharma1, José V Lafuente2, Dafin F Muresanu3a, Rudy J Castellani4, Mark A Smith5, Ala Nozari6, Ranjana Patnaik7, Z Ryan Tian8, Asya Ozhizilcik9, Stephen D Skaper10, Herbert Mössler11a, Aruna Sharma1

1International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden, 2Dept. of Neurosciences, University of Basque Country, Bilbao, Spain, 3Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, 4“RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania, 5University of Maryland, Dept. of Pathology, Baltimore, MD, USA, 6Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA 7Anesthesiology, Massachusetts General Hospital, Harvard University, Boston MA, USA, 8School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of technology, Banaras Hindu University, Varanasi, India, 9Dept. Chemistry & Biochemistry & 10Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA, 11Ever NeuroPharma, Oberburgau, Austria

**P103** - Sleep deprivation aggravates Alzheimer’s disease brain pathology. Enhanced neuroprotection by nanowired delivery of cerebrolysin with alpha melanocyte stimulating hormone and antibodies to alpha-synuclein

Aruna Sharma1*, José V Lafuente2, Dafin F Muresanu3a, Rudy J Castellani4, Mark A Smith5, Ala Nozari6, Ranjana Patnaik7, Z Ryan Tian8, Asya Ozhizilcik9, Herbert Mössler11a, Hari S Sharma1

1International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden, 2Dept. of Neurosciences, University of Basque Country, Bilbao, Spain, 3Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, 4“RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania, 5University of Maryland, Dept. of Pathology, Baltimore, MD, USA, 6Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA 7Anesthesiology, Massachusetts General Hospital, Harvard University, Boston MA, USA, 8School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of technology, Banaras Hindu University, Varanasi, India, 9Dept. Chemistry & Biochemistry & 10Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA, 11Ever NeuroPharma, Oberburgau, Austria

**P104** - The effect of crenezumab on beta-amyloid toxicity–induced synapse loss, neurofibrillary tangles and cell death in human neurons in vitro

Ben Chih, PhD, Reina A. Bassil, BS, Shirley Ng, BS, Maureen Beresini, PhD
Genentech, Inc., South San Francisco, CA, US

**Late Breaking Posters**

**LBP57** - Adult conditional BACE1 knockout mice exhibit axonal organization defects in the hippocampus

Robert Vassar, PhD
Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, USA

**LBP58** - Disease modifying therapy by targeting generic protein secondary structure of pathological oligomers at any stages of Alzheimer’s Disease models

Fernando Goni, PhD, Krystal Herline, PhD, Mitchell Marta-Ariza, MSc, Frances Prelli, MSc and Thomas Wisniewski, MD
1New York University School of Medicine, New York, USA
**Theme 11. New therapies and clinical trials**

**P5 - Therapeutic monitoring and prediction of the effectiveness of neurotrophic therapy in patients with mild cognitive impairment of the amnestic type**
Gavrilova S.1, Volpina O.1, Kolytkhalov I.1, Ponomareva E.1, Selezneva N.2, Fedorova Y. B., Karaev D.1, A. V. Kamynin
1Mental Health Research Center, Moscow, Russia, 2Institute of biorganic chemistry M.M.Semyonov and Y.A.Ovchinnikov Russian Academy of Sciences, Moscow, Russia

**P11 - 11β-hydroxysteroid dehydrogenase type 1 inhibitors pharmacological mechanism of potential therapeutic uses-a systematic review**
Sarah Gregory1, John W. Ketelbeys1, Tamara Miller2, Vincent S Ruffles2, Craig W. Ritchie1
1University of Edinburgh, Edinburgh, UK, 2Actigen Medical Ltd, Sydney, New South Wales, Australia

**P20 - SUVN-502 - Baseline characteristics of phase 2a study in moderate Alzheimer’s disease - First-in-class Triple combination of SUVN-502+Donepezil+Memantine - A Promising new approach for the symptomatic treatment of Alzheimer’s Disease**
Ramarthshna Nirogi, PhD1, Jyothsna Ravula, MS1, Satish Jetta, MS1, Koteshwara Mudigonda, PhD1, Vinod Kumar Goyal, MS1, Santosh Kumar Pandey, MS1, Copinadh Bhupapuneni, Ph.D1, Renny Abraham, Ph.D1, Vijay Benade, MS1, Pradeep Jayarajan, Ph.D1, Anil Shinde, Ph.D1, John Ieni, PhD1 and Venkat Jasti, MS1
Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

**P23 - Efficacy and safety of trigriluzole (BHV-4157) in patients with mild to moderate Alzheimer’s dementia: T2 PROTECT AD phase 2 study design**
Irfan A. Qureshi, M.D.1, Karen Messer, Ph.D.2, Kirsten Erichtson, Ph.D.2, Robert M. Berman, M.D.1, Carolyn Revta1, Timlan Ottersdorf, M.D.2, Braniko Huisa, M.D.2, Diane Jacobs, Ph.D.2, David Salmon, Ph.D.2, Doug Galasko, M.D.2, Thomas O. Obisesan, M.D.3, Neelum Aggarwal, M.D.4, Jacobo Mintzer, M.D.4, Judith Heidebrink, M.D.4, Amanda Smith, M.D.4, Miranda N. Reed, Ph.D.4, Holly C. Hunsberger, Ph.D.4, Lisa Donahue1, Kimberly Gentile1, David A. Stoch, Ph.D.4, Vladimir Conic, M.D.4, Howard Feldman, M.D.4
Bohavem Pharmaceuticals, Inc., New Haven, CT, USA, 2Alzheimer’s Disease Cooperative Study, University of California at San Diego, La Jolla, CA, USA, 3Howard University, Washington, DC, USA, 4Rush University Medical Center, Chicago, IL, USA, 5Roper St. Francis Hospital, Charleston, SC, USA, 6University of Michigan, Ann Arbor, MI, USA, 7University of South Florida Health Byrd Alzheimer Institute, Tampa, FL, USA, 8Auburn University, Auburn, AL, USA

**P56 - Gamma-secretase sequestration has multiple anti-amyloidogenic effects in vivo**
Bengt Winblad4, Gunnar Nordwall2,3, Ping Yan1, Johan Lundqvist2,3, Johan Sandin1,2,3, Henrik Biverståhl1, Henrik Zetterberg2, Rebeca Klintenberg1, Mats Ferm1, John R Cirrito1, Jin-Moo Lee1
1AlzCure Pharma AB, Drug Discovery & Development, Huddinge, Sweden, 2AlzCure Foundation, Preclinical Research, Huddinge, Sweden, 3Astra Zeneca R&D, CNS & Pain Aved, Södertälje, Sweden, 4Karolinska Institutet, Dept NVS, Div of Neurogeriatrics, Solna, Sweden, 5Washington University School of Medicine, Dept of Neurology, St Louis, USA, 6Karolinska University Hospital, Geriatric Clinical Trial Unit, Huddinge, Sweden, 7Sahlgrenska University Hospital, Clinical Neurochemistry Laboratory, Mölndal, Sweden

**P59 - Discovery of novel molecular chaperone modulators for the treatment of tau pathogenesis in Alzheimer’s disease**
Rajnish Kumar, PhD1, Pavel Pavlov, PhD1, Bengt Winblad, PhD1,2
1Department of Neuroradiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden, 2Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden

**P79 - CogniXtra preventive treatment affords neuroprotection against amyloid beta 25-35 peptide-induced toxicity in mice**
Francois J. Roman1, PhD, Johann Meunier1, PhD, Laura Ceolin1, PhD, Jean-Marie Butterlin1, PhD, Jean-Marie Butterlin1, PhD, Guillaume Blivet1, MS, Jacques Touchon1, MD, PhD
1Amygen, Montmélian-sur-Lez, France, 2Health Optimization Devices B.V, Maastricht, Netherlands, 3Montpellier, France, 4INSERM U1061 & Montpellier University, Montpellier, France

**P84 - Clinical Development of AXS-05 (Dextromethorphan/Bupropion) for Agitation Associated with Alzheimer’s Disease**
Harriot Tabuteau, MD1, Amanda Jones, PharmD1, Cedric O’Gorman, MD1
1Axsome Therapeutics Inc, USA

**P85 - Pharmacokinetics and safety profile of intravenous administration of Allopregnanolone in patients with early Alzheimer’s disease**
Gerson D. Hernandez1, MD, MPH1, Naoko Kono, MPH1, Claudia M. Lopez, BS1, Ron Irwin, Ph.D1, Kathleen Rodgers, Ph.D1, Jimmy Wu, PhD1, Rosario Mollo, PhD1, Sonia Pawluczzyk1, MD1, Meng Law, MD1, Wendy Mach, PhD1, Lon Schneider, MD, MS1, Roberta D. Brinton, PhD1
1Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA, 2Department of Preventive Medicine, Kech School of Medicine of the University of Southern California, Los Angeles, CA, USA, 3School of Pharmacy, University of Southern California, Los Angeles, CA, USA, 4TOMO Pharmacometrics, LLC, San Mateo, USA, 5Department of Psychiatry & The Behavioral Sciences, Kech School of Medicine of the University of Southern California, Los Angeles, CA, USA, 6Department of Radiology, Kech School of Medicine of the University of Southern California, Los Angeles, CA, USA
**PI05 - SM07883, a novel DYRK1A inhibitor, reduced Tau pathology – discovery and preclinical development of a potential therapeutic for Alzheimer’s disease**

Benoit Melchior, PhD1, Carolyn Lai1, Karen Duong-Pol1, Amanda Tijiro1, Lauren Pitizer1, Joshua Stewart1, Luis Dellamary1, Scott Anderson1, Brian Hofliena1, Chiao-Wen Chen, PhD1, Charlene Baroga, PhD1, Gopi Mittapalli, PhD1, Sunil KC, PhD1, Philippe Marchand, PhD1, and Yusuf Yazici, MD1

Samumed LLC, San Diego, USA

**PI06 - Apabetalone, a BET bromodomain inhibitor, suppresses inflammatory mediators in microglia and vascular endothelial cells that contribute to neurodegenerative disease**

Ewelina Kulibrowska1, Emily Daze1, Sylwia Wasial1, Dean Gilham1, Laura M. Tsujikawa1, Brooke Rahai1, Stephanie C. Stotz1, Christopher Halliday1, Ravi Jahagirdar1, Norman C. W. Wong1, and Michael Sweeney1

1Resverlogix Corp, Calgary, AB, Canada, 2Resverlogix Inc, San Francisco, CA, USA

**PI07 - Clinico-radiological recovery of ARIA-like events in corticosteroid-treated CAA-ri patients: implications for the management of ARIA side effects of anti-amyloid immunotherapy**

Fabrizio Piazza, PhD2,3, on behalf of The ICAIb International Network Collaborators and The CAA Study Group of the Italian Society of Neurology for dementia1, Japoc C. DiFrancesco1,2, Marialuisa Zedde1, Federica Angiulli2, Rosario Pascarella1, Roberto Marconi1, Francesco Perini1, Alberto Villarejo-Galende1, Mario Cirillo1, Berardino Orlandi1, Ilaria Masafulmi1, Mehdi Touati2, Hagiwara Yuta2, Juan F. Vázquez-Costa2, Massimo Caulo1, Shima Atsushi1, Alessia Giossi3, Ricardo Nitrini1, Massimo Muscicchio1,4, Main Network Collaborators: 1The inflammatory cerebral amyloid angiopathy and Alzheimer’s disease Biomarkers (ICAIb) International Network, University of Milano Bicocca, Monza, Italy, 2The CAA Study Group of the Italian Society of Neurology for dementia (SINdem), Italy, 3University of Milano Bicocca, Monza, Italy, 4National Research Council, Seegate, Italy, 5St. Bartolome Hospital, Vicenza, Italy, 6Hospital de Otorrinolaringologia CIBERNED, Madrid, Spain, 7Università della Campania L. Vanvitelli, Seconda Università degli Studi di Napoli, Italy, 8S S Filippo and Nicol Hosipital in Avezzano, L’Aquila, Italy, 9National Cerebral and Cardiovascular Center, Osaka, Japan, 10Dana-Farber Brigham and Women’s Hospital, Boston, Massachusetts, Inserm U1027, CNRS UMR 7225, Sorbonne Universités, Paris, France B USA, 11St. Mariana University School of Medicine, Japan, 12Instituto de Investigacion Sanitaria la Fe (IS La Fe), Valencia, Spain, 13University of C, d’Annunzio, Chieti, Italy, 14Kyoto University Graduate School of Medicine, Kyoto, Japan, 15O.U. of Neurology, ASST Cremona, Italy, 16University of Sao Paulo School of Medicine, Sao Paulo, Brazil

**PI08 - Clinical Pharmacokinetics and Pharmacodynamics Demonstrate Once-Weekly CoplexTM Donepezil Transdermal System as a Therapeutic Alternative to Daily Oral Aricept**

Bobby Singh, Corium International, Inc., 235 Constitution Drive, Menlo Park, California, USA

---

**Late Breaking Posters**

**LBP59 - Triple therapy with SUVN-502, a 5-HT6 antagonist, donepezil and memantine in moderate Alzheimer’s disease: Baseline patient characteristics in phase-2a study**

Alireza Atri1, MD, PhD1, Jeffrey L. Cummings, MD, ScD1, John Ieni, PhD2, Venkat Jasti, MS2, Ramatrishna Nirogi, PhD2

1Banner Sun Health Research Institute/Banner Health, Sun City, AZ, USA, 2Center for Brain/Mind medicine, Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA, 3Cleveland Clinic, Las Vegas, NV, USA, 4Discovery Research, Suven Life Sciences, Hyderabad, India

**LBP60 - Clinical polysomnography trial of suvorexant for treating insomnia in Alzheimer’s disease: trial design and baseline characteristics of participants**

W.J. Herring, MD1, P. Ceessay, PhD2, E. Snyder, PhD1, D. Bliwise, MD1, K. Budd, BS1, J. Hutzelmann, BS1, J. Stevens, BS1, D. Michelson, MD1

1Merck & Co, Inc, Kenilworth, NJ, USA, 2Emory University School of Medicine, Atlanta, GA, USA

**LBP61 - Neuroprotective effect of a new photobiomodulation technique against amyloid Aβ25-35 peptide induced toxicity in mice might support a novel hypothesis for therapeutic approach of Alzheimer’s disease**

Guillaume J. Blivet, MS1, Laura Auboyer, PhD1, Johann Meunier, PhD1, François J. Roman, PhD1, Jacques Touchon, MD, PhD1,2

1REGEnLIFE SAS, Montpellier, France, 2amylygen SAS, Montferrier-sur-Lez, France, 3INserm u1061, Montpellier, France, 4Neurology Department, University of Montpellier, France

**LBP62 - Interest of REGEnLIFE RgN530 photobiomodulation medical device for the treatment of Alzheimer’s disease: a double-blind, randomized sham-controlled trial to evaluate the safety and efficacy**

Audrey Gabelle1, MD, PhD1,2, Thibault Mura, MD, PhD1, Karim Bennys, MD2, Sophie Navucet, MS2, Martine Flores, MS2, Laura Auboyer, PhD1, Guillaume J. Blivet, MS3, Jacques Touchon, MD, PhD1,2

1Memory Research and Resources Center of Montpellier, Department of Neurology, Montpellier University Hospital, France, 2MUSE University, Inserm u1061, Montpellier, France, 3Department of Epidemiologic and Clinical Research, La Colombiere Hospital, Montpellier, France, 4REGEnLIFE SAS, Montpellier, France
CTAD 2018 would like to thank its privileged partners for their continued support of CTAD.

Gold Sponsors

[Logos of sponsors: Abbvie, Biogen, Eisai, Grifols, IQVIA, Janssen, Lilly, Lundbeck, Roche, Pfizer]
REGISTRATION

Early bird fees (until September 1)
Early bird registration (no lunches) 995€ - Early bird registration (3 lunches) 1124€

Early bird fees (after September 2)
Full registration (no lunches) 1287€ - Full registration (3 lunches) 1416€

Please note that registration to CTAD 2018 includes:
access to all conference sessions, attendee bag, one-year online subscription
to the Journal of Prevention of Alzheimer’s Disease (JPAD) and CTAD abstracts

You can register directly on our website www.ctad-alzheimer.com

ACCOMMODATIONS

Book your accommodation close to the Conference Venue
The Fairmont Rey Juan Carlos Hotel connected to the Conference Center is now sold out.

Our housing manager, Christophe Bascoul is dedicated to helping you find the best hotel close to the conference venue.

Contact: CTAD2018hotels@kris-events.com
Phone: +33 6 15 93 22 82
CTAD Congress
Phone: +33 (0)4 67 10 92 23
Email: ctad@ant-congres.com
www.ctad-alzheimer.com

Follow us on

@CTADConference  CTAD Alzheimer  CTAD Conference

#CTAD2018

www.ctad-alzheimer.com